

**Gerald Bronfman Department of Oncology Annual Report 2018**  
**Publications**

**Bassam Abdulkarim**

1. Leech AO, Vellanki SH, Rutherford EJ, Keogh A, Jahns H, Hudson L, O'Donovan N, Sabri S, **Abdulkarim B**, Sheehan KM, Kay EW, Young LS, Hill ADK, Smith YE, Hopkins AM. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings. *Breast Cancer Res.* 2018 Nov 20;20(1):140. doi: 10.1186/s13058-018-1064-1.
2. Chaddad A, Daniel P, Desrosiers C, Toews M, **Abdulkarim B**. Novel Radiomic Features based on Joint Intensity Matrices for Predicting Glioblastoma Patient Survival Time. *IEEE J Biomed Health Inform.* 2018 Apr 9. doi: 10.1109/JBHI.2018.2825027. [Epub ahead of print]
3. Chaddad A, Sabri S, Niazi T, **Abdulkarim B**. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients. *Med Biol Eng Comput.* 2018 Jun 19. doi: 10.1007/s11517-018-1858-4. [Epub ahead of print]
4. Shakir SI, Souhami L, Petrecca K, Mansure JJ, Singh K, Panet-Raymond V, Shenouda G, Al-Odaini AA, **Abdulkarim B**, Guiot MC. Prognostic factors for progression in atypical meningioma. *J Neurosurg.* 2018 Nov 1;129(5):1240-1248. doi: 10.3171/2017.6.JNS17120.
5. Kaur S, Ramdzan ZM, Guiot MC, Li L, Leduy L, Ramotar D, Sabri S, **Abdulkarim B**, Nepveu A. CUX1 stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the mono-alkylating agent temozolomide. *Neuro Oncol.* 2018 Mar 27;20(4):484-493. doi: 10.1093/neuonc/nox178.
6. Garnier D, Meehan B, Kislinger T, Daniel P, Sinha A, **Abdulkarim B**, Nakano I, Rak J. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. *Neuro Oncol.* 2018 Jan 22;20(2):236-248. doi: 10.1093/neuonc/nox142

**Sharon Abish**

1. Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, Kelso S, Sicheri F, Mikael LG, Hamel N, Bajic A, Dali R, Deshmukh S, Dervovic D, Schramek D, Guerin F, Taipale M, Nikbakht H, Majewski J, Moshous D, Charlebois J, **Abish S**, Bole-Feysot C, Nitschke P, Bader-Meunier B, Mitchell D, Thieblemont C, Battistella M, Gravel S, Nguyen VH, Conyers R, Diana JS, McCormack C, Prince HM, Besnard M, Blanche S, Ekert PG, Fraitag S, Foulkes WD, Fischer A, Neven B, Michonneau D, de Saint Basile G, Jabado N. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. *Nat Genet.* 2018 Dec;50(12):1650-1657. doi: 10.1038/s41588-018-0251-4. Epub 2018 Oct 29. Erratum in: *Nat Genet.* 2018 Nov 14;.
2. Ward LM, Ma J, Lang B, Ho J, Alos N, Matzinger MA, Shenouda N, Lentle B, Jaremko JL, Wilson B, Stephure D, Stein R, Sbrocchi AM, Rodd C, Lewis V, Israels S, Grant RM, Fernandez CV, Dix DB, Cummings EA, Couch R, Cairney E, Barr R, **Abish S**, Atkinson SA, Hay J, Rauch F, Moher D, Siminoski K, Halton J. Bone Morbidity and Recovery in Children With Acute Lymphoblastic Leukemia: Results of a Six-Year Prospective Cohort

Study. Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. *J Bone Miner Res.* 2018 Aug;33(8):1435-1443. doi: 10.1002/jbmr.3447. Epub 2018 May 22.

3. Arbiv OA, Cuvelier G, Klaassen RJ, Fernandez CV, Robitaille N, Steele M, Breakey V, **Abish S**, Wu J, Sinha R, Silva M, Goodyear L, Jardine L, Lipton JH, Corriveau-Bourque C, Brossard J, Michon B, Ghemlas I, Waespe N, Zlateska B, Sung L, Cada M, Dror Y. Molecular analysis and genotype-phenotype correlation of Diamond-Blackfan anemia. *Clin Genet.* 2018 Feb;93(2):320-328. doi: 10.1111/cge.13158. Epub 2017 Dec 27.

### Jason Agulnik

1. Kasymjanova G, Jagoe RT, Pepe C, Sakr L, Cohen V, Small D, Muanza TM, **Agulnik JS**. Does the presence of emphysema increase the risk of radiation pneumonitis in lung cancer patients? *Curr Oncol.* 2018 Dec;25(6):e610-e614. doi: 10.3747/co.25.4093. Epub 2018 Dec 1.
2. Melosky B, Cheema P, **Agulnik J**, Albadine R, Bebb DG, Blais N, Burkes R, Butts C, Card PB, Chan AMY, Hirsh V, Ionescu DN, Juergens R, Morzycki W, Poonja Z, Sangha R, Tehfe M, Tsao MS, Vincent M, Xu Z, Liu G. Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. *Curr Oncol.* 2018 Oct;25(5):317-328. doi: 10.3747/co.25.4379. Epub 2018 Oct 31. Review.
3. Kasymjanova G, Tran AT, Cohen V, Pepe C, Sakr L, Small D, **Agulnik JS**, Jagoe RT. The use of a standardized Chinese herbal formula in patients with advanced lung cancer: a feasibility study. *J Integr Med.* 2018 Nov;16(6):390-395. doi: 10.1016/j.joim.2018.09.001. Epub 2018 Sep 21.
4. van Kempen LC, Wang H, Aguirre ML, Spatz A, Kasymjanova G, Vilacha JF, Groves MR, **Agulnik J**, Small D. Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC. *J Thorac Oncol.* 2018 Sep;13(9):e161-e163. doi: 10.1016/j.jtho.2018.04.020. Epub 2018 Apr 25. No abstract available.
5. Wang H, **Agulnik J**, Kasymjanova G, Wang A, Jiménez P, Cohen V, Small D, Pepe C, Sakr L, Fiset PO, Auger M, Camilleri-Broet S, Alam El Din M, Chong G, van Kempen L, Spatz A. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. *Ann Oncol.* 2018 Jun 1;29(6):1417-1422. doi: 10.1093/annonc/mdy126.

### Moulay Alaoui-Jamali

1. Marques M, Jangal M, Wang LC, Kazanets A, da Silva SD, Zhao T, Lovato A, Yu H, Jie S, Del Rincon S, Mackey J, Damaraju S, **Alaoui-Jamali M**, Witcher M. Oncogenic activity of poly (ADP-ribose) glycohydrolase. *Oncogene.* 2018 Nov 20. doi: 10.1038/s41388-018-0568-6. [Epub ahead of print]
2. Li L, Guturi KKN, Gautreau B, Patel PS, Saad A, Morii M, Mateo F, Palomero L, Barbour H, Gomez A, Ng D, Kotlyar M, Pastrello C, Jackson HW, Khokha R, Jurisica I, Affar EB, Raught B, Sanchez O, **Alaoui-Jamali M**, Pujana MA, Hakem A, Hakem R. Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis. *J Clin Invest.* 2018 Oct 1;128(10):4525-4542. doi: 10.1172/JCI120401. Epub 2018 Aug 2.
3. Carnielli CM, Macedo CCS, De Rossi T, Granato DC, Rivera C, Domingues RR, Pauletti BA, Yokoo S, Heberle H, Busso-Lopes AF, Cervigne NK, Sawazaki-Calone I, Meirelles GV, Marchi FA, Telles GP, Minghim R, Ribeiro ACP, Brandão TB, de Castro G Jr,

González-Arriagada WA, Gomes A, Penteado F, Santos-Silva AR, Lopes MA, Rodrigues PC, Sundquist E, Salo T, da Silva SD, **Alaoui-Jamali MA**, Graner E, Fox JW, Coletta RD, Paes Leme AF. Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer. *Nat Commun.* 2018 Sep 5;9(1):3598. doi: 10.1038/s41467-018-05696-2.

4. Bijian K, Kaldre D, Wang TT, Su J, Bouttier M, Boucher A, **Alaoui-Jamali M**, White JH, Gleason JL. Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer. *J Steroid Biochem Mol Biol.* 2018 Mar;177:135-139. doi: 10.1016/j.jsbmb.2017.08.010. Epub 2017 Aug 25.

### **Thierry Alcindor**

1. **Alcindor T**, Al-Fakeeh A, Goulding K, Solymoss S, Ste-Marie N, Turcotte R. Venous Thromboembolism in Patients with Sarcoma: A Retrospective Study. *Oncologist.* 2018 Sep 26. pii: theoncologist.2018-0081. doi: 10.1634/theoncologist.2018-0081. [Epub ahead of print]
2. Chaigneau L, Patrikidou A, Ray-Coquard I, Valentin T, Linassier C, Bay JO, Moureau Zabotto L, Bompas E, Piperno-Neumann S, Penel N, **Alcindor T**, Laigre M, Guillemet C, Salas S, Hugli A, Domont J, Sunyach MP, Lecesne A, Blay JY, Nerich V, Isambert N. Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO). *Oncologist.* 2018 Aug;23(8):948-955. doi: 10.1634/theoncologist.2017-0136. Epub 2018 Jun 22.
3. Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, Chen EX, **Alcindor T**, Goffin JR, Korpanty GJ, Feilotter H, Tsao MS, Theis A, Tu D, Seymour L. A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. *Clin Colorectal Cancer.* 2018 Sep;17(3):231-239.e7. doi: 10.1016/j.clcc.2018.03.001. Epub 2018 Mar 8.
4. Gorelik N, Reddy SMV, Turcotte RE, Goulding K, Jung S, **Alcindor T**, Powell TI. Early detection of metastases using whole-body MRI for initial staging and routine follow-up of myxoid liposarcoma. *Skeletal Radiol.* 2018 Mar;47(3):369-379. doi: 10.1007/s00256-017-2845-9. Epub 2017 Dec 23.
5. Chan E, Chiorean EG, O'Dwyer PJ, Gabrail NY, **Alcindor T**, Potvin D, Chao R, Hurwitz H. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. *Cancer Chemother Pharmacol.* 2018 Feb;81(2):355-364. doi: 10.1007/s00280-017-3494-3. Epub 2017 Dec 13.

### **Joanne Alfieri**

1. Lucia F, Visvikis D, Vallières M, Desseroit MC, Miranda O, Robin P, Bonaffini PA, **Alfieri J**, Masson I, Mervoyer A, Reinhold C, Pradier O, Hatt M, Schick U. External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. *Eur J Nucl Med Mol Imaging.* 2018 Dec 7. doi: 10.1007/s00259-018-4231-9. [Epub ahead of print]
2. Piedimonte S, Richer L, Souhami L, Arseneau J, Fu L, Gilbert L, **Alfieri J**, Jardon K, Zeng XZ. Clinical significance of isolated tumor cells and micrometastasis in low-grade,

stage I endometrial cancer. *J Surg Oncol*. 2018 Dec;118(7):1194-1198. doi: 10.1002/jso.25259. Epub 2018 Oct 24.

3. Pembroke CA, **Alfieri J**, Biron A, Freeman C, Hijal T. Creation of an educational quality improvement program for radiation oncology residents. *Pract Radiat Oncol*. 2018 Mar - Apr;8(2):81-89. doi: 10.1016/j.prro.2017.11.007. Epub 2017 Nov 29.

### **Raquel Aloyz**

1. Galicia-Vázquez G, **Aloyz R**. Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes. *Front Oncol*. 2018 Sep 26;8:411. doi: 10.3389/fonc.2018.00411. eCollection 2018.
2. Sharif-Askari B, Amrein L, **Aloyz R**, Panasci L. PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines. *Breast Cancer Res Treat*. 2018 Nov;172(1):23-32. doi: 10.1007/s10549-018-4888-6. Epub 2018 Jul 23.
3. Galicia-Vázquez G, Smith S, **Aloyz R**. *Blood Cancer J*. 2018 Jan 24;8(1):13. doi: 10.1038/s41408-017-0039-2. No abstract available.

### **Armen Aprikian**

1. Olleik G, Kassouf W, **Aprikian A**, Hu J, Vanhuyse M, Cury F, Peacock S, Bonnevier E, Palenius E, Dragomir A. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. *J Natl Compr Canc Netw*. 2018 Nov;16(11):1340-1351. doi: 10.6004/jnccn.2018.7055.
2. Ouellet V, **Aprikian A**, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. *BMC Urol*. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.
3. Wissing M, Chevalier S, McKercher G, Laprise C, Aprikian S, O'Flaherty A, Scarlata E, Saad F, Carmel M, Lacombe L, Brimo F, Latour M, Ekindi-Ndongo N, Têtu B, **Aprikian A**. The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer. *World J Urol*. 2018 Aug 22. doi: 10.1007/s00345-018-2457-6. [Epub ahead of print]
4. Zakaria AS, Dragomir A, Brimo F, Kassouf W, Tanguay S, **Aprikian A**. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening. *BMC Urol*. 2018 Aug 20;18(1):69. doi: 10.1186/s12894-018-0384-x.
5. Wissing M, Brimo F, Chevalier S, Scarlata E, McKercher G, O'Flaherty A, Aprikian S, Thibodeau V, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, **Aprikian A**. Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer. *BJU Int*. 2018 Aug 16. doi: 10.1111/bju.14512. [Epub ahead of print]
6. Santa Mina D, Hilton WJ, Matthew AG, Awasthi R, Bousquet-Dion G, Alibhai SMH, Au D, Fleshner NE, Finelli A, Clarke H, **Aprikian A**, Tanguay S, Carli F. Prehabilitation for radical prostatectomy: A multicentre randomized controlled trial. *Surg Oncol*. 2018 Jun;27(2):289-298. doi: 10.1016/j.suronc.2018.05.010. Epub 2018 May 7.

- Leyh-Bannurah SR, Trudel D, Latour M, Zaffuto E, Grosset AA, Tam C, Ouellet V, Graefen M, Budäus L, **Aprikian AG**, Lacombe L, Fleshner NE, Gleave ME, Mes-Masson AM, Saad F, Karakiewicz PI. A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. *Pathol Oncol Res.* 2018 Apr 6. doi: 10.1007/s12253-018-0408-6. [Epub ahead of print]
- Kassouf W, **Aprikian A**, Saad F, Breau RH, Kulkarni G, Guttman DM, Bagshaw K, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Brimo F, Chung P, Drachenberg D, Fradet Y, Jacobsen N, Morash C, Shayegan B, Gotto G, Zlotta A, Fleshner N, Siemens DR, Black PC. Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. *Can Urol Assoc J.* 2018 Jul;12(7):E281-E297. doi: 10.5489/cuaj.5246. Epub 2018 Mar 19. No abstract available.
- Zakaria AS, Dragomir A, Kassouf W, Tanguay S, **Aprikian A**. Changes in the levels of testosterone profile over time in relation to clinical parameters in a cohort of patients with prostate cancer managed by active surveillance. *World J Urol.* 2018 Aug;36(8):1209-1217. doi: 10.1007/s00345-018-2270-2. Epub 2018 Mar 20.
- Dawe DE, Ye X, Czaykowski P, Jassal D, Singh H, Skarsgard D, **Aprikian A**, Mahmud SM. The effect of statin use on the incidence of prostate cancer: A population-based nested case-control study. *Int J Cancer.* 2018 Jul 1;143(1):190-198. doi: 10.1002/ijc.31295. Epub 2018 Feb 16.
- Bramhecha YM, Guérard KP, Rouzbeh S, Scarlata E, Brimo F, Chevalier S, Hamel L, Dragomir A, **Aprikian AG**, Lapointe J. Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention. *Mol Cancer Res.* 2018 Jan;16(1):115-123. doi: 10.1158/1541-7786.MCR-17-0270. Epub 2017 Oct 9.

### **Sylvie Aubin**

- Aubin S**, Rosberger Z, Hafez N, Noory MR, Perez S, Lehmann S, Batist G, Kavan P. Cancer!? I Don't Have Time for That: Impact of a Psychosocial Intervention for Young Adults with Cancer. *J Adolesc Young Adult Oncol.* 2018 Nov 28. doi: 10.1089/jayao.2017.0101. [Epub ahead of print]

### **Laurent Azoulay**

- Montastruc F, Renoux C, Dell'Aniello S, Simon TA, **Azoulay L**, Hudson M, Suissa S. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. *Rheumatology (Oxford).* 2018 Dec 7. doi: 10.1093/rheumatology/key352. [Epub ahead of print]
- Abrahami D, Douros A, Yin H, Yu OH, Faillie JL, Montastruc F, Platt RW, Bouganim N, **Azoulay L**. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. *BMJ.* 2018 Dec 5;363:k4880. doi: 10.1136/bmj.k4880.
- Rotshild V, **Azoulay L**, Feldhamer I, Perlman A, Glazer M, Muszkat M, Matok I. Calcium Channel Blockers and the Risk for Lung Cancer: A Population-Based Nested Case-Control Study. *Ann Pharmacother.* 2018 Nov 15;1060028018814684. doi: 10.1177/1060028018814684. [Epub ahead of print]

4. Klil-Drori AJ, Yin H, **Azoulay L**, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP). Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia. *Cancer*. 2018 Nov 13. doi: 10.1002/cncr.31835. [Epub ahead of print]
5. Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, **Azoulay L**. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. *BMJ*. 2018 Oct 24;363:k4209. doi: 10.1136/bmj.k4209.
6. Wu JW, **Azoulay L**, Huang A, Paterson M, Wu F, Secrest MH, Filion KB. Identification of incident pancreatic cancer in Ontario administrative health data: A validation study. *Pharmacoepidemiol Drug Saf*. 2018 Oct 4. doi: 10.1002/pds.4641. [Epub ahead of print]
7. Garfinkle R, Abou-Khalil M, Bhatnagar S, Wong-Chong N, **Azoulay L**, Morin N, Vasilevsky CA, Boutros M. A Comparison of Pathologic Outcomes of Open, Laparoscopic, and Robotic Resections for Rectal Cancer Using the ACS-NSQIP Proctectomy-Targeted Database: a Propensity Score Analysis. *J Gastrointest Surg*. 2018 Sep 27. doi: 10.1007/s11605-018-3974-8. [Epub ahead of print]
8. Douros A, Filion KB, Yin H, Yu OH, Etminan M, Udell JA, **Azoulay L**. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. *Diabetes Care*. 2018 Nov;41(11):2330-2338. doi: 10.2337/dc17-2280. Epub 2018 Aug 27.
9. Douros A, Abrahami D, Yin H, Yu OHY, Renoux C, Hudson M, **Azoulay L**. Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. *Epidemiology*. 2018 Nov;29(6):904-912. doi: 10.1097/EDE.0000000000000891.
10. Douros A, Dell'Aniello S, Yu OHY, Filion KB, **Azoulay L**, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. *BMJ*. 2018 Jul 18;362:k2693. doi: 10.1136/bmj.k2693.
11. Goulden R, Nguyen QD, **Azoulay L**. Risk of Bias in Study of Varenicline and Cardiovascular Outcomes. *Am J Respir Crit Care Med*. 2018 Sep 1;198(5):690-691. doi: 10.1164/rccm.201803-0423LE. No abstract available.
12. Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, **Azoulay L**. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. *BMJ*. 2018 Mar 21;360:k872. doi: 10.1136/bmj.k872.
13. Douros A, **Azoulay L**, Yin H, Suissa S, Renoux C. Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury. *J Am Coll Cardiol*. 2018 Mar 13;71(10):1105-1113. doi: 10.1016/j.jacc.2018.01.009.
14. Rotshild V, **Azoulay L**, Zarifeh M, Masarwa R, Hirsh-Racah B, Perlman A, Muszkat M, Matok I. The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies. *Drug Saf*. 2018 Jun;41(6):555-564. doi: 10.1007/s40264-018-0644-4. Review.
15. Puckrin R, Saltiel MP, Reynier P, **Azoulay L**, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. *Acta Diabetol*. 2018 May;55(5):503-514. doi: 10.1007/s00592-018-1116-0. Epub 2018 Feb 27. Review.

16. Suissa S, **Azoulay L**. Reply to P. Autier et al. *J Clin Oncol*. 2018 Mar 10;36(8):831-832. doi: 10.1200/JCO.2017.77.0057. Epub 2018 Jan 25. No abstract available.
17. Abrahami D, Yin H, Yu OHY, Pollak MN, **Azoulay L**. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes. *Epidemiology*. 2018 Mar;29(2):246-253. doi: 10.1097/EDE.0000000000000793.
18. Yu O, **Azoulay L**, Yin H, Filion KB, Suissa S. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia. *Am J Med*. 2018 Mar;131(3):317.e11-317.e22. doi: 10.1016/j.amjmed.2017.09.044. Epub 2017 Oct 12.
19. Davidson MA, Mattison DR, **Azoulay L**, Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. *Crit Rev Toxicol*. 2018 Jan;48(1):52-108. doi: 10.1080/10408444.2017.1351420. Epub 2017 Aug 17

#### **Boris Bahoric**

1. Chaddad A, Niazi T, Probst S, Bladou F, Anidjar M, **Bahoric B**. Predicting Gleason Score of Prostate Cancer Patients Using Radiomic Analysis. *Front Oncol*. 2018 Dec 18;8:630. doi: 10.3389/fonc.2018.00630. eCollection 2018.
2. Nabid A, Carrier N, Martin AG, Bahary JP, Lemaire C, Vass S, **Bahoric B**, Archambault R, Vincent F, Bettahar R, Duclos M, Garant MP, Souhami L. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. *Eur Urol*. 2018 Oct;74(4):432-441. doi: 10.1016/j.eururo.2018.06.018. Epub 2018 Jul 3.

#### **Mark Basik**

1. Hirukawa A, Smith HW, Zuo D, Dufour CR, Savage P, Bertos N, Johnson RM, Bui T, Bourque G, **Basik M**, Giguère V, Park M, Muller WJ. Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. *Nat Commun*. 2018 Jun 29;9(1):2547. doi: 10.1038/s41467-018-04864-8.
2. Mnatsakanyan R, Shema G, **Basik M**, Batist G, Borchers CH, Sickmann A, Zahedi RP. Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry. *Expert Rev Proteomics*. 2018 Jun;15(6):515-535. doi: 10.1080/14789450.2018.1483340
3. Goyette MA, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault MP, Johnson RM, Carmeliet P, **Basik M**, Gaboury L, Muller WJ, Park M, Roux PP, Gratton JP, Côté JF. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. *Cell Rep*. 2018 May 1;23(5):1476-1490. doi: 10.1016/j.celrep.2018.04.019.

#### **Gerald Batist**

1. Al-Thawadi H, Ghabreau L, Aboukassim T, Yasmeen A, Vranic S, **Batist G**, Al Moustafa AE. Co-Incidence of Epstein-Barr Virus and High-Risk Human Papillomaviruses in Cervical Cancer of Syrian Women. *Front Oncol*. 2018 Jul 2;8:250. doi: 10.3389/fonc.2018.00250. eCollection 2018.
2. Mnatsakanyan R, Shema G, Basik M, **Batist G**, Borchers CH, Sickmann A, Zahedi RP. Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry. *Expert Rev Proteomics*. 2018 Jun;15(6):515-535. doi: 10.1080/14789450.2018.1483340.

3. Alahmad YM, Aljaber M, Saleh AI, Yalcin HC, Aboukassim T, Yasmeeen A, **Batist G**, Moustafa AA. Effect of cell-phone radiofrequency on angiogenesis and cell invasion in human head and neck cancer cells. *Head Neck*. 2018 Oct;40(10):2166-2171. doi: 10.1002/hed.25210. Epub 2018 May 13.
4. Stewart DJ, Stewart AA, Wheatley-Price P, **Batist G**, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R. The importance of greater speed in drug development for advanced malignancies. *Cancer Med*. 2018 May;7(5):1824-1836. doi: 10.1002/cam4.1454. Epub 2018 Mar 30.
5. Felfoul O, Mohammadi M, Taherkhani S, Lanauze D, Zhong Xu Y, Lafleur M, Gaboury L, Tabrizian M, Vuong T, **Batist G**, Beauchemin N, Radzioch D, Martel S. [Delivery in hypoxic tumor regions of a chemotherapeutic agent encapsulated in nanoliposomes carried by magnetoaerotactic bacteria]. *Med Sci (Paris)*. 2018 Mar;34(3):197-199. doi: 10.1051/medsci/20183403002. Epub 2018 Mar 16. French. No abstract available.
6. Saleh AI, Mohamed I, Mohamed AA, Abdelkader M, Yalcin HC, Aboukassim T, **Batist G**, Yasmeeen A, Moustafa AA. *Elaeagnus angustifolia* Plant Extract Inhibits Angiogenesis and Downgrades Cell Invasion of Human Oral Cancer Cells via Erk1/Erk2 Inactivation. *Nutr Cancer*. 2018 Feb-Mar;70(2):297-305. doi: 10.1080/01635581.2018.1412472. Epub 2018 Jan 4.
7. Banerji U, Dean EJ, Pérez-Fidalgo JA, **Batist G**, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. *Clin Cancer Res*. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24.
8. Ashour AA, Haik MY, Sadek KW, Yalcin HC, Bitharas J, Aboukassim T, **Batist G**, Yasmeeen A, Al Moustafa AE. Substantial Toxic Effect of Water-Pipe Smoking on the Early Stage of Embryonic Development. *Nicotine Tob Res*. 2018 Mar 6;20(4):502-507. doi: 10.1093/ntr/ntx135.

#### **Nicole Beauchemin**

1. Felfoul O, Mohammadi M, Taherkhani S, Lanauze D, Zhong Xu Y, Lafleur M, Gaboury L, Tabrizian M, Vuong T, **Batist G**, **Beauchemin N**, Radzioch D, Martel S. [Delivery in hypoxic tumor regions of a chemotherapeutic agent encapsulated in nanoliposomes carried by magnetoaerotactic bacteria]. *Med Sci (Paris)*. 2018 Mar;34(3):197-199. doi: 10.1051/medsci/20183403002. Epub 2018 Mar 16. French. No abstract available.

#### **Franck Bladou**

1. Chaddad A, Niazi T, Probst S, **Bladou F**, Anidjar M, Bahoric B. Predicting Gleason Score of Prostate Cancer Patients Using Radiomic Analysis. *Front Oncol*. 2018 Dec 18;8:630. doi: 10.3389/fonc.2018.00630. eCollection 2018.
2. Gauvin S, Rompré-Brodeur A, Chaussé G, Anidjar M, **Bladou F**, Probst S. 18F-fluorocholine positron emission tomography-computed tomography (18F-FCH PET/CT)



for staging of high-risk prostate cancer patients. *Can Urol Assoc J*. 2018 Sep 27. doi: 10.5489/cuaj.5142. [Epub ahead of print]

3. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, **Bladou F**, Villeirs GM, Viridi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med*. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.

### Christoph Borchers

1. Han J, Higgins R, Lim MD, Atkinson K, Yang J, Lin K, **Borchers CH**. Isotope-labeling derivatization with 3-nitrophenylhydrazine for LC/multiple-reaction monitoring-mass-spectrometry-based quantitation of carnitines in dried blood spots. *Anal Chim Acta*. 2018 Dec 11;1037:177-187. doi: 10.1016/j.aca.2018.01.045. Epub 2018 Feb 5.
2. Michaud SA, Sinclair NJ, Pětrošová H, Palmer AL, Pistawka AJ, Zhang S, Hardie DB, Mohammed Y, Eshghi A, Richard VR, Sickmann A, **Borchers CH**. Molecular phenotyping of laboratory mouse strains using 500 multiple reaction monitoring mass spectrometry plasma assays. *Commun Biol*. 2018 Jun 27;1:78. doi: 10.1038/s42003-018-0087-6. eCollection 2018.
3. Popp R, Li H, **Borchers CH**. Immuno-MALDI (iMALDI) mass spectrometry for the analysis of proteins in signaling pathways. *Expert Rev Proteomics*. 2018 Sep;15(9):701-708. doi: 10.1080/14789450.2018.1516147. Epub 2018 Sep 17.
4. Zahedi RP, Parker CE, **Borchers CH**. Immuno-MALDI-TOF-MS in the Clinic. *Clin Chem*. 2018 Sep;64(9):1271-1272. doi: 10.1373/clinchem.2018.292136. Epub 2018 Jul 17. No abstract available.
5. Penn AM, Bibok MB, Saly VK, Coutts SB, Lesperance ML, Balshaw RF, Votova K, Croteau NS, Trivedi A, Jackson AM, Hegedus J, Klourfeld E, Yu AXY, Zerna C, Modi J, Barber PA, Hoag G, **Borchers CH**; SpecTRA study group. Validation of a proteomic biomarker panel to diagnose minor-stroke and transient ischaemic attack: phase 2 of SpecTRA, a large scale translational study. *Biomarkers*. 2018 Dec;23(8):793-803. doi: 10.1080/1354750X.2018.1499130. Epub 2018 Aug 23.
6. Wölter M, Okai CA, Smith DS, Ruß M, Rath W, Pecks U, **Borchers CH**, Glocker MO. Maternal Apolipoprotein B100 Serum Levels are Diminished in Pregnancies with Intrauterine Growth Restriction and Differentiate from Controls. *Proteomics Clin Appl*. 2018 Nov;12(6):e1800017. doi: 10.1002/prca.201800017. Epub 2018 Jul 23.
7. Mahdavi S, Jenkins DJA, **Borchers CH**, El-Sohemy A. Genetic Variation in 9p21 and the Plasma Proteome. *J Proteome Res*. 2018 Aug 3;17(8):2649-2656. doi: 10.1021/acs.jproteome.8b00117. Epub 2018 Jul 19.
8. Mnatsakanyan R, Shema G, Basik M, Batist G, **Borchers CH**, Sickmann A, Zahedi RP. Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry. *Expert Rev Proteomics*. 2018 Jun;15(6):515-535. doi: 10.1080/14789450.2018.1483340.

9. Bhowmick P, Mohammed Y, **Borchers CH**. MRMAssayDB: an integrated resource for validated targeted proteomics assays. *Bioinformatics*. 2018 Oct 15;34(20):3566-3571. doi: 10.1093/bioinformatics/bty385.
10. Popp R, Basik M, Spatz A, Batist G, Zahedi RP, **Borchers CH**. How iMALDI can improve clinical diagnostics. *Analyst*. 2018 May 15;143(10):2197-2203. doi: 10.1039/c8an00094h.
11. Parker CE, **Borchers CH**. The Special Issue: Clinical Proteomics for Precision Medicine. *Proteomics Clin Appl*. 2018 Mar;12(2). doi: 10.1002/prca.201600144. No abstract available.
12. Luehr TC, Koide EM, Wang X, Han J, **Borchers CH**, Helbing CC. Metabolomic insights into the effects of thyroid hormone on *Rana [Lithobates] catesbeiana* metamorphosis using whole-body Matrix Assisted Laser Desorption/Ionization-Mass Spectrometry Imaging (MALDI-MSI). *Gen Comp Endocrinol*. 2018 Sep 1;265:237-245. doi: 10.1016/j.ygcen.2018.02.012. Epub 2018 Feb 19.
13. Liu T, Wang RX, Han J, Hao CZ, Qiu YL, Yan YY, Li LT, Wang NL, Gong JY, Lu Y, Zhang MH, Xie XB, Yang JC, You YJ, Li JQ, Knisely AS, **Borchers CH**, Ling V, Wang JS. Comprehensive bile acid profiling in hereditary intrahepatic cholestasis: Genetic and clinical correlations. *Liver Int*. 2018 Sep;38(9):1676-1685. doi: 10.1111/liv.13714. Epub 2018 Mar 12.
14. Penn AM, Bibok MB, Saly VK, Coutts SB, Lesperance ML, Balshaw RF, Votova K, Croteau NS, Trivedi A, Jackson AM, Hegedus J, Klourfeld E, Yu AYG, Zerna C, **Borchers CH**; SpecTRA study group. Verification of a proteomic biomarker panel to diagnose minor stroke and transient ischaemic attack: phase 1 of SpecTRA, a large scale translational study. *Biomarkers*. 2018 May - Jun;23(4):392-405. doi: 10.1080/1354750X.2018.1434681. Epub 2018 Feb 12.
15. Penn AM, Saly V, Trivedi A, Lesperance ML, Votova K, Jackson AM, Croteau NS, Balshaw RF, Bibok MB, Smith DS, Lam KK, Morrison J, Lu L, Coutts SB, **Borchers CH**. Differential Proteomics for Distinguishing Ischemic Stroke from Controls: a Pilot Study of the SpecTRA Project. *Transl Stroke Res*. 2018 Dec;9(6):590-599. doi: 10.1007/s12975-018-0609-z. Epub 2018 Jan 24.
16. Dilworth D, Gudavicius G, Xu X, Boyce AKJ, O'Sullivan C, Serpa JJ, Bilenky M, Petrochenko EV, **Borchers CH**, Hirst M, Swayne LA, Howard P, Nelson CJ. The prolyl isomerase FKBP25 regulates microtubule polymerization impacting cell cycle progression and genomic stability. *Nucleic Acids Res*. 2018 Mar 16;46(5):2459-2478. doi: 10.1093/nar/gky008.
17. Perzanowska A, Fatalska A, Wojtas G, Lewandowicz A, Michalak A, Krasowski G, **Borchers CH**, Dadlez M, Domanski D. An MRM-Based Cytokeratin Marker Assay as a Tool for Cancer Studies: Application to Lung Cancer Pleural Effusions. *Proteomics Clin Appl*. 2018 Mar;12(2). doi: 10.1002/prca.201700084. Epub 2018 Feb 7.
18. Brodie NI, Hugué R, Zhang T, Viner R, Zabrouskov V, Pan J, Petrotchenko EV, **Borchers CH**. Top-Down Hydrogen-Deuterium Exchange Analysis of Protein Structures Using Ultraviolet Photodissociation. *Anal Chem*. 2018 Mar 6;90(5):3079-3082. doi: 10.1021/acs.analchem.7b03655. Epub 2018 Feb 1.
19. Jardim A, Hardie DB, Boitz J, **Borchers CH**. Proteomic Profiling of *Leishmania donovani* Promastigote Subcellular Organelles. *J Proteome Res*. 2018 Mar 2;17(3):1194-1215. doi: 10.1021/acs.jproteome.7b00817. Epub 2018 Feb 5.

20. Eshghi A, **Borchers CH**. Multiple Reaction Monitoring Using Double Isotopologue Peptide Standards for Protein Quantification. *Methods Mol Biol*. 2018;1788:193-214. doi: 10.1007/7651\_2017\_112.
21. Han J, Higgins R, Lim MD, Lin K, Yang J, **Borchers CH**. Short-Term Stabilities of 21 Amino Acids in Dried Blood Spots. *Clin Chem*. 2018 Feb;64(2):400-402. doi: 10.1373/clinchem.2017.278457. Epub 2017 Nov 2. No abstract available.
22. Mohammed Y, Pan J, Zhang S, Han J, **Borchers CH**. ExSTA: External Standard Addition Method for Accurate High-Throughput Quantitation in Targeted Proteomics Experiments. *Proteomics Clin Appl*. 2018 Mar;12(2). doi: 10.1002/prca.201600180. Epub 2017 Oct 25.

### **Manuel Borod**

1. Hochberg U, Perez J, **Borod M**. New frontier: cancer pain management clinical fellowship. *Support Care Cancer*. 2018 Jul;26(7):2453-2457. doi: 10.1007/s00520-018-4085-5. Epub 2018 Feb 10.

### **Nathanial Bouganim**

1. Abrahami D, Douros A, Yin H, Yu OH, Faillie JL, Montastruc F, Platt RW, **Bouganim N**, Azoulay L. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. *BMJ*. 2018 Dec 5;363:k4880. doi: 10.1136/bmj.k4880.
2. Khosrow-Khavar F, Yin H, Barkun A, **Bouganim N**, Azoulay L. Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer. *Ann Oncol*. 2018 Mar 1;29(3):744-748. doi: 10.1093/annonc/mdx822.
3. Desforges P, Esfahani K, **Bouganim N**. Programmed Cell Death Ligand 1-Induced Coma From Diffuse Cerebritis. *J Oncol Pract*. 2018 Feb;14(2):134-135. doi: 10.1200/JOP.2017.024992. Epub 2017 Oct 10. No abstract available.

### **Pnina Brodt**

1. Vaniotis G, Moffett S, Sulea T, Wang N, Elahi SM, Lessard E, Baardsnes J, Perrino S, Durocher Y, Frystyk J, Massie B, **Brodt P**. Enhanced anti-metastatic bioactivity of an IGF-TRAP re-engineered to improve physicochemical properties. *Sci Rep*. 2018 Nov 26;8(1):17361. doi: 10.1038/s41598-018-35407-2.
2. Vaniotis G, Rayes RF, Qi S, Milette S, Wang N, Perrino S, Bourdeau F, Nyström H, He Y, Lamarche-Vane N, **Brodt P**. Collagen IV-conveyed signals can regulate chemokine production and promote liver metastasis. *Oncogene*. 2018 Jul;37(28):3790-3805. doi: 10.1038/s41388-018-0242-z. Epub 2018 Apr 13.
3. Rayes RF, Milette S, Fernandez MC, Ham B, Wang N, Bourdeau F, Perrino S, Yakar S, **Brodt P**. Loss of neutrophil polarization in colon carcinoma liver metastases of mice with an inducible, liver-specific IGF-I deficiency. *Oncotarget*. 2018 Feb 28;9(21):15691-15704. doi: 10.18632/oncotarget.24593. eCollection 2018 Mar 20.

### **Julia Burnier**

1. Yang SYC, Lheureux S, Karakasis K, **Burnier JV**, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM. Landscape of genomic alterations in high-grade serous ovarian cancer

from exceptional long- and short-term survivors. *Genome Med.* 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x.

### **Prosanto Chaudhury**

1. Kao LS, Ball CG, **Chaudhury PK**; for Members of the Evidence Based Reviews in Surgery Group. Evidence-based Reviews in Surgery: Early Cholecystectomy for Cholecystitis. *Ann Surg.* 2018 Dec;268(6):940-942. doi: 10.1097/SLA.0000000000002867.
2. Sandal S, Paraskevas S, Cantarovich M, Baran D, **Chaudhury P**, Tchervenkov JI, Sapir-Pichhadze R. Renal resistance thresholds during hypothermic machine perfusion and transplantation outcomes - a retrospective cohort study. *Transpl Int.* 2018 Jun;31(6):658-669. doi: 10.1111/tri.13146. Epub 2018 Mar 25.

### **Robin Cohen**

1. Milman E, Neimeyer RA, Fitzpatrick M, MacKinnon CJ, Muis KR, **Cohen SR**. Prolonged grief symptomatology following violent loss: the mediating role of meaning. *Eur J Psychotraumatol.* 2018 Aug 14;8(Suppl 6):1503522. doi: 10.1080/20008198.2018.1503522. eCollection 2017.
2. Chan LS, Macdonald ME, Carnevale FA, **Cohen SR**. 'I'm only dealing with the acute issues': How medical ward 'busyness' constrains care of the dying. *Health (London).* 2018 Sep;22(5):451-468. doi: 10.1177/1363459317708822. Epub 2017 May 29.

### **Victor Cohen**

1. Kasymjanova G, Tran AT, **Cohen V**, Pepe C, Sakr L, Small D, Agulnik JS, Jagoe RT. The use of a standardized Chinese herbal formula in patients with advanced lung cancer: a feasibility study. *J Integr Med.* 2018 Nov;16(6):390-395. doi: 10.1016/j.joim.2018.09.001. Epub 2018 Sep 21.

### **Fabio Cury**

1. Olleik G, Kassouf W, Aprikian A, Hu J, Vanhuyse M, **Cury F**, Peacock S, Bonnevier E, Palenius E, Dragomir A. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. *J Natl Compr Canc Netw.* 2018 Nov;16(11):1340-1351. doi: 10.6004/jnccn.2018.7055.
2. Tsui JM, Mihalciou C, **Cury FL**. Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab. *Cureus.* 2018 Feb 27;10(2):e2238. doi: 10.7759/cureus.2238.

### **Richard Dalfen**

1. Ibrahim M, Muanza T, Smirnow N, Sateren W, Fournier B, Kavan P, Palumbo M, **Dalfen R**, Dalzell MA. A Pilot Randomized Controlled Trial on the Effects of a Progressive Exercise Program on the Range of Motion and Upper Extremity Grip Strength in Young Adults With Breast Cancer. *Clin Breast Cancer.* 2018 Feb;18(1):e55-e64. doi: 10.1016/j.clbc.2017.06.007. Epub 2017 Jun 24.

### **Sonia del Rincon**

1. Marques M, Jangal M, Wang LC, Kazanets A, da Silva SD, Zhao T, Lovato A, Yu H, Jie S, **Del Rincon S**, Mackey J, Damaraju S, Alaoui-Jamali M, Witcher M. Oncogenic

- activity of poly (ADP-ribose) glycohydrolase. *Oncogene*. 2018 Nov 20. doi: 10.1038/s41388-018-0568-6. [Epub ahead of print]
2. Dahabieh MS, Di Pietro E, Jangal M, Goncalves C, Witcher M, Braverman NE, **Del Rincón SV**. Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism. *Biochim Biophys Acta Rev Cancer*. 2018 Aug;1870(1):103-121. doi: 10.1016/j.bbcan.2018.07.004. Epub 2018 Aug 6. Review.
  3. Robichaud N, Hsu BE, Istomine R, Alvarez F, Blagih J, Ma EH, Morales SV, Dai DL, Li G, Souleimanova M, Guo Q, **Del Rincon SV**, Miller WH Jr, Ramón Y Cajal S, Park M, Jones RG, Piccirillo CA, Siegel PM, Sonenberg N. Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils. *Proc Natl Acad Sci U S A*. 2018 Mar 6;115(10):E2202-E2209. doi: 10.1073/pnas.1717439115. Epub 2018 Feb 20.

### **Slobodan Devic**

1. Aldelaijan S, **Devic S**. Comparison of dose response functions for EBT3 model GafChromic™ film dosimetry system. *Phys Med*. 2018 May;49:112-118. doi: 10.1016/j.ejmp.2018.05.014.
2. Tomic N, Papaconstadopoulos P, Aldelaijan S, Rajala J, Seuntjens J, **Devic S**. Image quality for radiotherapy CT simulators with different scanner bore size. *Phys Med*. 2018 Jan;45:65-71. doi: 10.1016/j.ejmp.2017.11.017. Epub 2017 Dec 19.
3. Aldelaijan S, Tomic N, Papaconstadopoulos P, Schneider J, Seuntjens J, Shih S, Lewis D, **Devic S**. Technical Note: Response time evolution of XR-QA2 GafChromic™ film models. *Med Phys*. 2018 Jan;45(1):488-492. doi: 10.1002/mp.12689. Epub 2017 Dec 12.
4. Liang LH, Tomic N, Vuong T, Aldelaijan S, Bekerat H, DeBlois F, Seuntjens J, **Devic S**. Physics aspects of the Papillon technique-Five decades later. *Brachytherapy*. 2018 Jan - Feb;17(1):234-243. doi: 10.1016/j.brachy.2017.09.016.

### **Marie Duclos**

1. Nabid A, Carrier N, Martin AG, Bahary JP, Lemaire C, Vass S, Bahoric B, Archambault R, Vincent F, Bettahar R, **Duclos M**, Garant MP, Souhami L. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. *Eur Urol*. 2018 Oct;74(4):432-441. doi: 10.1016/j.eururo.2018.06.018. Epub 2018 Jul 3.
2. Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, Lau H, **Duclos M**, Parliament M, Morton G, Hamstra D, Seider M, Lock MI, Patel M, Gay H, Vigneault E, Winter K, Sandler H. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. *JAMA Oncol*. 2018 Jun 14;4(6):e180039. doi: 10.1001/jamaoncol.2018.0039. Epub 2018 Jun 14.

### **Shirin Enger**

1. Famulari G, Renaud MA, Poole CM, Evans MDC, Seuntjens J, **Enger SA**. RapidBrachyMCTPS: a Monte Carlo-based treatment planning system for brachytherapy applications. *Phys Med Biol*. 2018 Aug 30;63(17):175007. doi: 10.1088/1361-6560/aad97a.

2. DeCunha JM, **Enger SA**. A new delivery system to resolve dosimetric issues in intravascular brachytherapy. *Brachytherapy*. 2018 May - Jun;17(3):634-643. doi: 10.1016/j.brachy.2018.01.012. Epub 2018 Mar 5.
3. Mann-Krzisnik D, Verhaegen F, **Enger SA**. The influence of tissue composition uncertainty on dose distributions in brachytherapy. *Radiother Oncol*. 2018 Mar;126(3):394-410. doi: 10.1016/j.radonc.2018.01.007. Epub 2018 Feb 7. Review.
4. Famulari G, Pater P, **Enger SA**. Microdosimetric Evaluation of Current and Alternative Brachytherapy Sources-A Geant4-DNA Simulation Study. *Int J Radiat Oncol Biol Phys*. 2018 Jan 1;100(1):270-277. doi: 10.1016/j.ijrobp.2017.09.040. Epub 2017 Sep 25.

### Michael Evans

1. Montgomery L, **Evans M**, Liang L, Maglieri R, Kildea J. The effect of the flattening filter on photoneutron production at 10 MV in the Varian TrueBeam linear accelerator. *Med Phys*. 2018 Oct;45(10):4711-4719. doi: 10.1002/mp.13148. Epub 2018 Sep 14.
2. Famulari G, Renaud MA, Poole CM, **Evans MDC**, Seuntjens J, Enger SA. RapidBrachyMCTPS: a Monte Carlo-based treatment planning system for brachytherapy applications. *Phys Med Biol*. 2018 Aug 30;63(17):175007. doi: 10.1088/1361-6560/aad97a.

### Marc Fabian

1. Nishimura T, Fakim H, Brandmann T, Youn JY, Gingras AC, Jinek M, **Fabian MR**. Human MARF1 is an endoribonuclease that interacts with the DCP1:2 decapping complex and degrades target mRNAs. *Nucleic Acids Res*. 2018 Dec 14;46(22):12008-12021. doi: 10.1093/nar/gky1011.
2. Duchaine TF, **Fabian MR**. Mechanistic Insights into MicroRNA-Mediated Gene Silencing. *Cold Spring Harb Perspect Biol*. 2018 Jun 29. pii: a032771. doi: 10.1101/cshperspect.a032771. [Epub ahead of print]
3. Brandmann T, Fakim H, Padamsi Z, Youn JY, Gingras AC, **Fabian MR**, Jinek M. Molecular architecture of LSM14 interactions involved in the assembly of mRNA silencing complexes. *EMBO J*. 2018 Apr 3;37(7). pii: e97869. doi: 10.15252/embj.201797869. Epub 2018 Mar 6.
4. Cieplak-Rotowska MK, Tarnowski K, Rubin M, **Fabian MR**, Sonenberg N, Dadlez M, Niedzwiecka A. Structural Dynamics of the GW182 Silencing Domain Including its RNA Recognition motif (RRM) Revealed by Hydrogen-Deuterium Exchange Mass Spectrometry. *J Am Soc Mass Spectrom*. 2018 Jan;29(1):158-173. doi: 10.1007/s13361-017-1830-9. Epub 2017 Oct 27.
5. Wu MK, Vujanic GM, Fahiminiya S, Watanabe N, Thorner PS, O'Sullivan MJ, **Fabian MR**, Foulkes WD. Anaplastic sarcomas of the kidney are characterized by DICER1 mutations. *Mod Pathol*. 2018 Jan;31(1):169-178. doi: 10.1038/modpathol.2017.100. Epub 2017 Sep 1.

### Sergio Faria

1. Diamant A, Chatterjee A, **Faria S**, Naqa IE, Bahig H, Filion E, Robinson C, Al-Halabi H, Seuntjens J. Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)? *Radiother Oncol*. 2018 Sep;128(3):513-519. doi:10.1016/j.radonc.2018.05.012. Epub 2018 May 22.

### **Cristiano Ferrario**

1. Borges VF, **Ferrario C**, Aucoin N, Falkson C, Khan Q, Krop I, Welch S, Conlin A, Chaves J, Bedard PL, Chamberlain M, Gray T, Vo A, Hamilton E. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial. *JAMA Oncol.* 2018 Sep 1;4(9):1214-1220. doi: 10.1001/jamaoncol.2018.1812.

### **Lorenzo Ferri**

1. Renaud S, Seitlinger J, St-Pierre D, Garfinkle R, Al Lawati Y, Guerrera F, Ruffini E, Falcoz PE, Massard G, **Ferri L**, Spicer J. Prognostic value of neutrophil to lymphocyte ratio in lung metastasectomy for colorectal cancer. *Eur J Cardiothorac Surg.* 2018 Dec 1. doi: 10.1093/ejcts/ezy388. [Epub ahead of print]
2. Eustache J, **Ferri LE**, Feldman LS, Lee L, Spicer JD. Enhanced recovery after pulmonary surgery. *J Thorac Dis.* 2018 Nov;10(Suppl 32):S3755-S3760. doi: 10.21037/jtd.2018.09.61.
3. Cools-Lartigue J, **Ferri L**. Radiation is Not a Solution for Suboptimal Surgery. A Response to the Conclusions Drawn From the Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma With or Without Neoadjuvant Chemoradiotherapy Study. *Ann Surg.* 2018 Sep 20. doi: 10.1097/SLA.0000000000003020. [Epub ahead of print] No abstract available.
4. Minnella EM, Awasthi R, Loiselle SE, Agnihotram RV, **Ferri LE**, Carli F. Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial. *JAMA Surg.* 2018 Sep 5. doi: 10.1001/jamasurg.2018.1645. [Epub ahead of print]
5. St-Louis E, Gowing SD, Mossallanejad P, Leimanis ML, Mueller C, **Ferri LE**. Outcomes after completion total gastrectomy for gastric remnant cancer: experience from a Canadian tertiary centre. *Can J Surg.* 2018 Aug;61(4):270-277.
6. Renaud S, Seitlinger J, Lawati YA, Guerrera F, Falcoz PE, Massard G, **Ferri L**, Spicer J. *Ann Surg.* Anatomical Resections Improve Survival Following Lung Metastasectomy of Colorectal Cancer Harboring KRAS Mutations. 2018 May 17. doi: 10.1097/SLA.0000000000002829. [Epub ahead of print]
7. **Ferri L**. Clinical Complete Response After Neoadjuvant Therapy for Esophageal Cancer: What's Lurking Under the Surface? *Ann Surg Oncol.* 2018 Aug;25(8):2120-2121. doi: 10.1245/s10434-018-6514-6. Epub 2018 May 14. No abstract available.
8. Gosselin-Tardif A, Lie J, Nicolau I, Molina JC, Cools-Lartigue J, Feldman L, Spicer J, Mueller C, **Ferri L**. Gastrectomy with Extended Lymphadenectomy: a North American Perspective. *J Gastrointest Surg.* 2018 Mar;22(3):414-420. doi: 10.1007/s11605-017-3633-5. Epub 2017 Nov 9.
9. Molina JC, Misariu AM, Nicolau I, Spicer J, Mulder D, **Ferri LE**, Mueller CL. Same day discharge for benign laparoscopic hiatal surgery: a feasibility analysis. *Surg Endosc.* 2018 Feb;32(2):937-944. doi: 10.1007/s00464-017-5769-5. Epub 2017 Aug 4.

### **William Foulkes**

1. de Kock L, Hillmer M, Wagener R, Soglio DB, Sabbaghian N, Siebert R, Priest JR, Miller M, **Foulkes WD**. Further evidence that full gene deletions of DICER1 predispose

- to DICER1 syndrome. *Genes Chromosomes Cancer*. 2018 Dec 30. doi: 10.1002/gcc.22728. [Epub ahead of print] No abstract available.
2. Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, Baxter S, Brody L, Cook-Deegan R, Coffin A, Couch FJ, Craft B, Currie R, Dlott CC, Dolman L, den Dunnen JT, Dyke SOM, Domchek SM, Easton D, Fischmann Z, **Foulkes WD**, Garber J, Goldgar D, Goldman MJ, Goodhand P, Harrison S, Haussler D, Kato K, Knoppers B, Markello C, Nussbaum R, Offit K, Plon SE, Rashbass J, Rehm HL, Robson M, Rubinstein WS, Stoppa-Lyonnet D, Tavtigian S, Thorogood A, Zhang C, Zimmermann M; BRCA Challenge Authors, Burn J, Chanock S, Rättsch G, Spurdle AB. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. *PLoS Genet*. 2018 Dec 26;14(12):e1007752. doi: 10.1371/journal.pgen.1007752. eCollection 2018 Dec.
  3. Roussel L, Landekic M, Golizeh M, Gavino C, Zhong MC, Chen J, Faubert D, Blanchet-Cohen A, Dansereau L, Parent MA, Marin S, Luo J, Le C, Ford BR, Langelier M, King IL, Divangahi M, **Foulkes WD**, Veillette A, Vinh DC. Loss of human ICOSL results in combined immunodeficiency. *J Exp Med*. 2018 Dec 3;215(12):3151-3164. doi: 10.1084/jem.20180668.
  4. Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, Kelso S, Sicheri F, Mikael LG, Hamel N, Bajic A, Dali R, Deshmukh S, Dervovic D, Schramek D, Guerin F, Taipale M, Nikbakht H, Majewski J, Moshous D, Charlebois J, Abish S, Bole-Feysot C, Nitschke P, Bader-Meunier B, Mitchell D, Thieblemont C, Battistella M, Gravel S, Nguyen VH, Conyers R, Diana JS, McCormack C, Prince HM, Besnard M, Blanche S, Ekert PG, Fraitag S, **Foulkes WD**, Fischer A, Neven B, Michonneau D, de Saint Basile G, Jabado N. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. *Nat Genet*. 2018 Dec;50(12):1650-1657. doi: 10.1038/s41588-018-0251-4. Epub 2018 Oct 29. Erratum in: *Nat Genet*. 2018 Nov 14;.
  5. Fahiminiya S, Sabbaghian N, Albrecht S, Nadaf J, Callegaro-Filho D, **Foulkes WD**. Ovarian small cell carcinoma in one of a pair of monozygous twins. *Fam Cancer*. 2018 Oct 4. doi: 10.1007/s10689-018-0108-0. [Epub ahead of print]
  6. Goudie C, Cullinan N, Villani A, Mathews N, van Engelen K, Malkin D, Irwin MS, **Foulkes WD**. Retrospective evaluation of a decision-support algorithm (MIPOGG) for genetic referrals for children with neuroblastic tumors. *Pediatr Blood Cancer*. 2018 Dec;65(12):e27390. doi: 10.1002/pbc.27390. Epub 2018 Aug 16.
  7. Goudie C, Hannah-Shmouni F, Kavak M, Stratakis CA, **Foulkes WD**. 65 YEARS OF THE DOUBLE HELIX: Endocrine tumour syndromes in children and adolescents. *Endocr Relat Cancer*. 2018 Aug;25(8):T221-T244. doi: 10.1530/ERC-18-0160. Review.
  8. **Foulkes WD**, Bertherat J, Eng C. 65 YEARS OF THE DOUBLE HELIX: It's all in the DNA: understanding and managing endocrine neoplasms. *Endocr Relat Cancer*. 2018 Aug;25(8):E5-E7. doi: 10.1530/ERC-18-0283. No abstract available.
  9. Chong AS, Fahiminiya S, Strother D, Priest J, Albrecht S, Rivera B, **Foulkes WD**. Revisiting pleuropulmonary blastoma and atypical choroid plexus papilloma in a young child: DICER1 syndrome or not? *Pediatr Blood Cancer*. 2018 Oct;65(10):e27294. doi: 10.1002/pbc.27294. Epub 2018 Jun 26. No abstract available.



10. de Kock L, Fahiminiya S, Fiset PO, Astigarraga I, Nguyen VH, Albrecht S, **Foulkes WD**. Infantile Pulmonary Teratoid Tumor. *N Engl J Med*. 2018 Jun 7;378(23):2238-2240. doi: 10.1056/NEJMc1803354. No abstract available.
11. Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, **Foulkes WD**, Ainsworth P, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. *Gynecol Oncol*. 2018 Jul;150(1):85-91. doi: 10.1016/j.ygyno.2018.05.011. Epub 2018 May 21.
12. Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, **Foulkes WD**, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. *JAMA Oncol*. 2018 Aug 1;4(8):1059-1065. doi: 10.1001/jamaoncol.2018.0211.
13. Bah I, Fahiminiya S, Bégin LR, Hamel N, D'Agostino MD, Tanguay S, **Foulkes WD**. Atypical tuberous sclerosis complex presenting as familial renal cell carcinoma with leiomyomatous stroma. *J Pathol Clin Res*. 2018 Jul;4(3):167-174. doi: 10.1002/cjp2.104. Epub 2018 Jun 13.
14. Caimari F, Kumar AV, Kurzawinski T, Butler G, Sabbaghian N, **Foulkes WD**, Korbonits M. A novel DICER1 mutation in familial multinodular goitre. *Clin Endocrinol (Oxf)*. 2018 Jul;89(1):110-112. doi: 10.1111/cen.13613. Epub 2018 May 4. No abstract available.
15. Vinh DC, Palma L, Storrington J, **Foulkes WD**. GATA2 Deficiency Due to de Novo Complete Monoallelic Deletion in an Adolescent With Myelodysplasia. *J Pediatr Hematol Oncol*. 2018 May;40(4):e225-e228. doi: 10.1097/MPH.0000000000001136.
16. Bouron-Dal Soglio D, de Kock L, Gauci R, Sabbaghian N, Thomas E, Atkinson HC, Pachter N, Ryan S, Walsh JP, Kumarasinghe MP, Carpenter K, Aydoğan A, Stewart CJR, **Foulkes WD**, Choong CS. A Case Report of Syndromic Multinodular Goitre in Adolescence: Exploring the Phenotype Overlap between Cowden and DICER1 Syndromes. *Eur Thyroid J*. 2018 Jan;7(1):44-50. doi: 10.1159/000481620. Epub 2017 Nov 21.
17. Kim SJ, Huzarski T, Gronwald J, Singer CF, Møller P, Lynch HT, Armel S, Karlan BY, **Foulkes WD**, Neuhausen SL, Senter L, Eisen A, Eng C, Panchal S, Pal T, Olopade O, Zakalik D, Lubinski J, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group. Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. *Int J Epidemiol*. 2018 Mar 13. doi: 10.1093/ije/dyy039. [Epub ahead of print]
18. Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Ooster PJ, van Asperen CJ, Vasen H, Kiemeny LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, **Foulkes WD**, Boshari T,

- Davidson R, Ruijs M, Helderma-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. *Br J Cancer*. 2018 Mar 20;118(6):e17. doi: 10.1038/bjc.2018.11. Epub 2018 Mar 6.
19. Toland AE, Forman A, Couch FJ, Culver JO, Eccles DM, **Foulkes WD**, Hogervorst FBL, Houdayer C, Levy-Lahad E, Monteiro AN, Neuhausen SL, Plon SE, Sharan SK, Spurdle AB, Szabo C, Brody LC; BIC Steering Committee. Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices. *NPJ Genom Med*. 2018 Feb 15;3:7. doi: 10.1038/s41525-018-0046-7. eCollection 2018.
20. Wasserman JD, Sabbaghian N, Fahiminiya S, Chami R, Mete O, Acker M, Wu MK, Shlien A, de Kock L, **Foulkes WD**. DICER1 Mutations Are Frequent in Adolescent-Onset Papillary Thyroid Carcinoma. *J Clin Endocrinol Metab*. 2018 May 1;103(5):2009-2015. doi: 10.1210/jc.2017-02698.
21. Lammert J, Lubinski J, Gronwald J, Huzarski T, Armel S, Eisen A, Meschino WS, Lynch HT, Snyder C, Eng C, Olopade OI, Ginsburg O, **Foulkes WD**, Elser C, Cohen SA, Kiechle M, Narod SA, Kotsopoulos J. Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat*. 2018 Jun;169(3):561-571. doi: 10.1007/s10549-018-4694-1. Epub 2018 Feb 5.
22. Sabbaghian N, Digilio MC, Blue GM, Revil T, Winlaw DS, **Foulkes WD**. Analysis of DICER1 in familial and sporadic cases of transposition of the great arteries. *Congenit Heart Dis*. 2018 May;13(3):401-406. doi: 10.1111/chd.12578. Epub 2018 Feb 5
23. Agaimy A, **Foulkes WD**. Hereditary SWI/SNF complex deficiency syndromes. *Semin Diagn Pathol*. 2018 May;35(3):193-198. doi: 10.1053/j.semdp.2018.01.002. Epub 2018 Feb 1. Review.
24. Rivera B, Polak P, **Foulkes WD**. Monogenic Diseases of DNA Repair. *N Engl J Med*. 2018 Feb 1;378(5):491. doi: 10.1056/NEJMc1716072. No abstract available.
25. Ko KP, Kim SJ, Huzarski T, Gronwald J, Lubinski J, Lynch HT, Armel S, Park SK, Karlan B, Singer CF, Neuhausen SL, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group. The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. *Int J Cancer*. 2018 Jun 1;142(11):2263-2272. doi: 10.1002/ijc.31257. Epub 2018 Jan 25.

26. Solarski M, Rotondo F, **Foulkes WD**, Priest JR, Syro LV, Butz H, Cusimano MD, Kovacs K. DICER1 gene mutations in endocrine tumors. *Endocr Relat Cancer*. 2018 Mar;25(3):R197-R208. doi: 10.1530/ERC-17-0509. Epub 2018 Jan 12. Review.
27. de Kock L, Geoffrion D, Rivera B, Wagener R, Sabbaghian N, Bens S, Ellezam B, Bouron-Dal Soglio D, Ordóñez J, Sacharow S, Polo Nieto JF, Guillerman RP, Vujanic GM, Priest JR, Siebert R, **Foulkes WD**. Multiple DICER1-related tumors in a child with a large interstitial 14q32 deletion. *Genes Chromosomes Cancer*. 2018 May;57(5):223-230. doi: 10.1002/gcc.22523. Epub 2018 Feb 10.
28. Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrone K, Richardson K, Eccles D, Jensen T, Othter PJ, van Asperen CJ, Vasen H, Kiemeny LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, **Foulkes WD**, Boshari T, Davidson R, Ruijs M, Helderma-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. *Br J Cancer*. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4. Erratum in: *Br J Cancer*. 2018 Mar 06;.
29. Baert A, Machackova E, Coene I, Cremin C, Turner K, Portugal-Todd C, Asrat MJ, Nuk J, Mindlin A, Young S, MacMillan A, Van Maerken T, Trbusek M, McKinnon W, Wood ME, **Foulkes WD**, Santamariña M, de la Hoya M, Foretova L, Poppe B, Vral A, Rosseel T, De Leeneer K, Vega A, Claes KBM. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11. *Hum Mutat*. 2018 Apr;39(4):515-526. doi: 10.1002/humu.23390. Epub 2018 Jan 22.
30. Apellaniz-Ruiz M, de Kock L, Sabbaghian N, Guaraldi F, Ghizzoni L, Beccuti G, **Foulkes WD**. Familial multinodular goiter and Sertoli-Leydig cell tumors associated with a large intragenic in-frame DICER1 deletion. *Eur J Endocrinol*. 2018 Feb;178(2):K11-K19. doi: 10.1530/EJE-17-0904. Epub 2017 Nov 29

31. Goudie C, Witkowski L, Vairy S, McCluggage WG, **Foulkes WD**. Paediatric ovarian tumours and their associated cancer susceptibility syndromes. *J Med Genet*. 2018 Jan;55(1):1-10. doi: 10.1136/jmedgenet-2017-104926. Epub 2017 Nov 24. Review.
32. McCluggage WG, Irving JA, Chong AS, Clarke BA, Young RH, **Foulkes WD**, Rivera B. Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis. *Am J Surg Pathol*. 2018 Jan;42(1):137-139. doi: 10.1097/PAS.0000000000000981. No abstract available.
33. Wu MK, Vujanic GM, Fahiminiya S, Watanabe N, Thorner PS, O'Sullivan MJ, Fabian MR, **Foulkes WD**. Anaplastic sarcomas of the kidney are characterized by DICER1 mutations. *Mod Pathol*. 2018 Jan;31(1):169-178. doi: 10.1038/modpathol.2017.100. Epub 2017 Sep 1.
34. Saskin A, de Kock L, Sabbaghian N, Apellaniz-Ruiz M, Bozkurt C, Bouron-Dal Soglio D, **Foulkes WD**. A case of neuroblastoma in DICER1 syndrome: Chance finding or noncanonical causation? *Pediatr Blood Cancer*. 2018 Jan;65(1). doi: 10.1002/pbc.26715. Epub 2017 Aug 2.

#### **Eduardo Franco**

1. Hurtado-Salgado E, Ortiz-Panozo E, Salmerón J, Saavedra-Lara N, Kuri-Morales P, Pesqueira-Villegas E, Luna-Gordillo R, **Franco EL**, Lazcano-Ponce E. Use of HPV testing in cervical cancer screening services in Mexico, 2008-2018: a nationwide database study. *Salud Publica Mex*. 2018 Nov-Dic;60(6):722-733. doi: 10.21149/9891.
2. **Franco EL**. Prevention of cervical cancer in Latin America: Future challenges and opportunities. *Salud Publica Mex*. 2018 Nov-Dic;60(6):609-611. doi: 10.21149/10071. No abstract available.
3. Isidean SD, Wang Y, Mayrand MH, Ratnam S, Coutlée F, **Franco EL**, Abrahamowicz M; CCCaST Study Group. Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening. *Int J Cancer*. 2018 Nov 9. doi: 10.1002/ijc.31970. [Epub ahead of print]
4. Malagón T, Kulasingam S, Mayrand MH, Ogilvie G, Smith L, Bouchard C, Gotlieb W, **Franco EL**. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study. *Lancet Oncol*. 2018 Dec;19(12):1569-1578. doi: 10.1016/S1470-2045(18)30536-9. Epub 2018 Nov 1. Erratum in: *Lancet Oncol*. 2019 Jan;20(1):e10.
5. Cook DA, Smith LW, Law JH, Mei W, Gondara L, van Niekerk DJ, Ceballos KM, Jang D, Chernesky M, **Franco EL**, Ogilvie GS, Coldman AJ, Krajden M. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial. *J Clin Virol*. 2018 Nov;108:32-37. doi: 10.1016/j.jcv.2018.09.004. Epub 2018 Sep 10.
6. Bao X, Hanson AL, Madeleine MM, Wang SS, Schwartz SM, Newell F, Pettersson-Kymmer U, Hemminki K, Tiewes S, Steinberg W, Rader JS, Castro F, Safaeian M, **Franco EL**, Coutlée F, Ohlsson C, Cortes A, Marshall M, Mukhopadhyay P, Cremin K, Johnson LG, Garland SM, Tabrizi SN, Wentzensen N, Sitas F, Trimble C, Little J, Cruickshank M, Frazer IH, Hildesheim A, Brown MA, Duncan EL, Sun YP, Leo PJ. HLA and KIR Associations of Cervical Neoplasia. *J Infect Dis*. 2018 Nov 5;218(12):2006-2015. doi: 10.1093/infdis/jiy483.

7. Brenner DR, Poirier AE, Walter SD, King WD, **Franco EL**, Demers PA, Villeneuve PJ, Ruan Y, Khandwala F, Grevers X, Nuttall R, Smith L, De P, Volesky K, O'Sullivan D, Hystad P, Friedenreich CM; ComPARE Study Group. Estimating the current and future cancer burden in Canada: methodological framework of the Canadian population attributable risk of cancer (ComPARE) study. *BMJ Open*. 2018 Aug 1;8(7):e022378. doi: 10.1136/bmjopen-2018-022378.
8. Chandler E, Ding L, Gorbach P, **Franco EL**, Brown DA, Widdice LE, Bernstein DI, Kahn JA. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction. *J Adolesc Health*. 2018 Jul;63(1):43-49. doi: 10.1016/j.jadohealth.2018.01.005.
9. Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, Ceballos K, Quinlan D, Lee M, Martin RE, Gentile L, Peacock S, Stuart GCE, **Franco EL**, Coldman AJ. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. *JAMA*. 2018 Jul 3;320(1):43-52. doi: 10.1001/jama.2018.7464. Erratum in: *JAMA*. 2018 Dec 4;320(21):2273.
10. Malagón T, Laurie C, **Franco EL**. Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review. *Expert Rev Vaccines*. 2018 May;17(5):395-409. doi: 10.1080/14760584.2018.1471986. Epub 2018 May 21. Review.
11. El-Zein M, Bouten S, Louvanto K, Gilbert L, Gotlieb W, Hemmings R, Behr MA, **Franco EL**; CASSIS Study Group. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study. *Gynecol Oncol*. 2018 Jun;149(3):491-497. doi: 10.1016/j.ygyno.2018.04.004. Epub 2018 Apr 17.
12. **Franco EL**, Shinder GA, Tota JE, Volesky K, Isidean SD. Journal editors as curators of scholarship: A case study in repairing the scientific record. *Prev Med*. 2018 May;110:114-115. doi: 10.1016/j.ypmed.2018.02.027. No abstract available.
13. **Franco EL**. Self-sampling for cervical cancer screening: Empowering women to lead a paradigm change in cancer control. *Curr Oncol*. 2018 Feb;25(1):e1-e3. doi: 10.3747/co.25.3969. Epub 2018 Feb 28. No abstract available.
14. Leo PJ, Madeleine MM, Wang S, Schwartz SM, Newell F, Pettersson-Kymmer U, Hemminki K, Hallmans G, Tiews S, Steinberg W, Rader JS, Castro F, Safaeian M, **Franco EL**, Coutlée F, Ohlsson C, Cortes A, Marshall M, Mukhopadhyay P, Cremin K, Johnson LG, Trimble CL, Garland S, Tabrizi SN, Wentzensen N, Sitas F, Little J, Cruickshank M, Frazer IH, Hildesheim A, Brown MA. Correction: Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study. *PLoS Genet*. 2018 Mar 1;14(3):e1007257. doi: 10.1371/journal.pgen.1007257. eCollection 2018 Mar.
15. Saccucci M, **Franco EL**, Ding L, Bernstein DI, Brown D, Kahn JA. Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection. *Sex Transm Dis*. 2018 Apr;45(4):260-265. doi: 10.1097/OLQ.0000000000000731.
16. Greenwald ZR, Fregnani JH, Longatto-Filho A, Watanabe A, Mattos JSC, Vazquez FL, **Franco EL**. The performance of mobile screening units in a breast cancer screening

- program in Brazil. *Cancer Causes Control*. 2018 Feb;29(2):233-241. doi: 10.1007/s10552-017-0995-7. Epub 2017 Dec 18.
17. Smith C, Ding L, Gorbach PM, **Franco EL**, Kahn JA. Who's Not Protected in the Herd? Factors Associated with Vaccine-Type HPV in Unvaccinated Women. *J Pediatr Adolesc Gynecol*. 2018 Apr;31(2):89-93. doi: 10.1016/j.jpap.2017.09.008. Epub 2017 Sep 21.
  18. Malagón T, Burchell A, El-Zein M, Guénoun J, Tellier PP, Coutlée F, **Franco EL**; HITCH study group. Y Chromosome DNA in Women's Vaginal Samples as a Biomarker of Recent Vaginal Sex and Condom Use With Male Partners in the HPV Infection and Transmission Among Couples Through Heterosexual Activity Cohort Study. *Sex Transm Dis*. 2018 Jan;45(1):28-34. doi: 10.1097/OLQ.0000000000000688.

### Carolyn Freeman

1. Xing S, **Freeman CR**, Jung S, Turcotte R, Levesque IR. Probabilistic classification of tumour habitats in soft tissue sarcoma. *NMR Biomed*. 2018 Nov;31(11):e4000. doi: 10.1002/nbm.4000. Epub 2018 Aug 16.
2. Pembroke CA, Alfieri J, Biron A, **Freeman C**, Hijal T. Creation of an educational quality improvement program for radiation oncology residents. *Pract Radiat Oncol*. 2018 Mar - Apr;8(2):81-89. doi: 10.1016/j.prro.2017.11.007. Epub 2017 Nov 29.
3. Montgomery L, Fava P, **Freeman CR**, Hijal T, Maietta C, Parker W, Kildea J. Development and implementation of a radiation therapy incident learning system compatible with local workflow and a national taxonomy. *J Appl Clin Med Phys*. 2018 Jan;19(1):259-270. doi: 10.1002/acm2.12218. Epub 2017 Nov 22.

### Vincent Giguère

1. Hirukawa A, Smith HW, Zuo D, Dufour CR, Savage P, Bertos N, Johnson RM, Bui T, Bourque G, Basik M, **Giguère V**, Park M, Muller WJ. Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. *Nat Commun*. 2018 Jun 29;9(1):2547. doi: 10.1038/s41467-018-04864-8.
2. Singh BK, Sinha RA, Tripathi M, Mendoza A, Ohba K, Sy JAC, Xie SY, Zhou J, Ho JP, Chang CY, Wu Y, **Giguère V**, Bay BH, Vanacker JM, Ghosh S, Gauthier K, Hollenberg AN, McDonnell DP, Yen PM. Thyroid hormone receptor and ER $\alpha$  coordinately regulate mitochondrial fission, mitophagy, biogenesis, and function. *Sci Signal*. 2018 Jun 26;11(536). pii: eaam5855. doi: 10.1126/scisignal.aam5855.
3. Audet-Walsh É, Vernier M, Yee T, Laflamme C, Li S, Chen Y, **Giguère V**. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer. *Mol Cancer Res*. 2018 Sep;16(9):1396-1405. doi: 10.1158/1541-7786.MCR-17-0410. Epub 2018 May 21.
4. B'chir W, Dufour CR, Ouellet C, Yan M, Tam IS, Andrzejewski S, Xia H, Nabata K, St-Pierre J, **Giguère V**. Divergent Role of Estrogen-Related Receptor  $\alpha$  in Lipid- and Fasting-Induced Hepatic Steatosis in Mice. *Endocrinology*. 2018 May 1;159(5):2153-2164. doi: 10.1210/en.2018-00115.
5. **Giguère V**. Canonical signaling and nuclear activity of mTOR—a teamwork effort to regulate metabolism and cell growth. *FEBS J*. 2018 May;285(9):1572-1588. doi: 10.1111/febs.14384. Epub 2018 Jan 31. Review.

6. Kim SY, Yang CS, Lee HM, Kim JK, Kim YS, Kim YR, Kim JS, Kim TS, Yuk JM, Dufour CR, Lee SH, Kim JM, Choi HS, **Giguère V**, Jo EK. ESRRRA (estrogen-related receptor  $\alpha$ ) is a key coordinator of transcriptional and post-translational activation of autophagy to promote innate host defense. *Autophagy*. 2018;14(1):152-168. doi: 10.1080/15548627.2017.1339001. Epub 2017 Sep 1.

### Lucy Gilbert

1. Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, **Gilbert L**, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. *Clin Cancer Res*. 2018 Nov 9. doi: 10.1158/1078-0432.CCR-18-2474. [Epub ahead of print]
2. Piedimonte S, Richer L, Souhami L, Arseneau J, Fu L, **Gilbert L**, Alfieri J, Jardon K, Zeng XZ. Clinical significance of isolated tumor cells and micrometastasis in low-grade, stage I endometrial cancer. *J Surg Oncol*. 2018 Dec;118(7):1194-1198. doi: 10.1002/jso.25259. Epub 2018 Oct 24.
3. El-Zein M, Bouten S, Louvanto K, **Gilbert L**, Gotlieb W, Hemmings R, Behr MA, Franco EL; CASSIS Study Group. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study. *Gynecol Oncol*. 2018 Jun;149(3):491-497. doi: 10.1016/j.ygyno.2018.04.004. Epub 2018 Apr 17.
4. Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, Sundfelt K, Kjær SK, Hruban RH, Shih IM, Wang TL, Kurman RJ, Springer S, Ptak J, Popoli M, Schaefer J, Silliman N, Dobbyn L, Tanner EJ, Angarita A, Lycke M, Jochumsen K, Afsari B, Danilova L, Levine DA, Jardon K, Zeng X, Arseneau J, Fu L, Diaz LA Jr, Karchin R, Tomasetti C, Kinzler KW, Vogelstein B, Fader AN, **Gilbert L**, Papadopoulos N. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. *Sci Transl Med*. 2018 Mar 21;10(433). pii: eaap8793. doi: 10.1126/scitranslmed.aap8793.

### Walter Gotlieb

1. Matanes E, Abitbol J, Kessous R, Kogan L, Oceau D, Lau S, Salvador S, **Gotlieb WH**. Oncologic and Surgical Outcomes of Robotic Versus Open Radical Hysterectomy for Cervical Cancer. *J Obstet Gynaecol Can*. 2018 Dec 7. pii: S1701-2163(18)30755-2. doi: 10.1016/j.jogc.2018.09.013. [Epub ahead of print].
2. Malagón T, Kulasingam S, Mayrand MH, Ogilvie G, Smith L, Bouchard C, **Gotlieb W**, Franco EL. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study. *Lancet Oncol*. 2018 Dec;19(12):1569-1578. doi: 10.1016/S1470-2045(18)30536-9. Epub 2018 Nov 1. Erratum in: *Lancet Oncol*. 2019 Jan;20(1):e10.
3. Laskov I, Kessous R, Abitbol J, Kogan L, Badeghiesh A, Tagalakis V, Cohen S, Salvador S, Lau S, **Gotlieb WH**; SOGC Communities of Practice. Risk of Thromboembolic Disease With Cost Estimates in Patients Undergoing Robotic Assisted Surgery for Endometrial Cancer and Review of the Literature. *J Obstet Gynaecol Can*. 2018 Dec;40(12):1571-1579. doi: 10.1016/j.jogc.2018.04.003. Epub 2018 Sep 24.

4. Piedimonte S, Czuzoj-Shulman N, **Gotlieb W**, Abenhaim HA. Robotic Radical Hysterectomy for Cervical Cancer: A Population-Based Study of Adoption and Immediate Postoperative Outcomes in the United States. *J Minim Invasive Gynecol*. 2018 Sep 5. pii: S1553-4650(18)30428-X. doi: 10.1016/j.jmig.2018.08.012. [Epub ahead of print]
5. McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, **Gotlieb WH**, Hoskins P, Kim RH; BRCA TtoT Community of Practice. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. *J Med Genet*. 2018 Sep;55(9):571-577. doi: 10.1136/jmedgenet-2018-105472. Epub 2018 Jul 24.
6. Kogan L, Oceau D, Amajoud Z, Abitbol J, Laskov I, Ferenczy A, Pelmus M, Eisenberg N, Kessous R, Lau S, Yasmeen A, **Gotlieb WH**, Salvador S. Impact of lower uterine segment involvement in type II endometrial cancer and the unique mutational profile of serous tumors. *Gynecol Oncol Rep*. 2018 Mar 19;24:43-47. doi: 10.1016/j.gore.2018.03.004. eCollection 2018 May.
7. El-Zein M, Bouten S, Louvanto K, Gilbert L, **Gotlieb W**, Hemmings R, Behr MA, Franco EL; CASSIS Study Group. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study. *Gynecol Oncol*. 2018 Jun;149(3):491-497. doi: 10.1016/j.ygyno.2018.04.004. Epub 2018 Apr 17.
8. Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, **Gotlieb WH**, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. *BMC Cancer*. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.
9. Kessous R, Oceau D, Klein K, Tonin PN, Greenwood CMT, Pelmus M, Laskov I, Kogan L, Salvador S, Lau S, Yasmeen A, **Gotlieb WH**. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. *Gynecol Oncol*. 2018 Mar;148(3):553-558. doi: 10.1016/j.ygyno.2018.01.017. Epub 2018 Feb 1.
10. How JA, O'Farrell P, Amajoud Z, Lau S, Salvador S, How E, **Gotlieb WH**. Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. *Minerva Ginecol*. 2018 Apr;70(2):194-214. doi: 10.23736/S0026-4784.17.04179-X. Epub 2017 Nov 28. Review.

### **Celia Greenwood**

1. Das S, Lecours Boucher X, Rogers C, Makowski C, Chouinard-Decorte F, Oros Klein K, Beck N, Rioux P, Brown ST, Mohaddes Z, Zweber C, Foing V, Forest M, O'Donnell KJ, Clark J, Meaney MJ, **Greenwood CMT**, Evans AC. Integration of "omics" Data and Phenotypic Data Within a Unified Extensible Multimodal Framework. *Front Neuroinform*. 2018 Dec 18;12:91. doi: 10.3389/fninf.2018.00091. eCollection 2018.
2. Manousaki D, Dudding T, Haworth S, Hsu YH, Liu CT, Medina-Gómez C, Voortman T, van der Velde N, Melhus H, Robinson-Cohen C, Cousminer DL, Nethander M,



- Vandenput L, Noordam R, Forgetta V, **Greenwood CMT**, Biggs ML, Psaty BM, Rotter JI, Zemel BS, Mitchell JA, Taylor B, Lorentzon M, Karlsson M, Jaddoe VVW, Tiemeier H, Campos-Obando N, Franco OH, Utterlinden AG, Broer L, van Schoor NM, Ham AC, Ikram MA, Karasik D, de Mutsert R, Rosendaal FR, den Heijer M, Wang TJ, Lind L, Orwoll ES, Mook-Kanamori DO, Michaëlsson K, Kestenbaum B, Ohlsson C, Mellström D, de Groot LCPGM, Grant SFA, Kiel DP, Zillikens MC, Rivadeneira F, Sawcer S, Timpson NJ, Richards JB. Low-Frequency Synonymous Coding Variation in CYP2R1 Has Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis. *Am J Hum Genet.* 2018 Dec 6;103(6):1053. doi: 10.1016/j.ajhg.2018.11.010. No abstract available.
3. Jiang L, Zhao K, Klein K, Canty AJ, Oualkacha K, **Greenwood CMT**. Investigating potential causal relationships between SNPs, DNA methylation and HDL. *BMC Proc.* 2018 Sep 17;12(Suppl 9):20. doi: 10.1186/s12919-018-0117-x. eCollection 2018.
  4. Zhao K, Jiang L, Klein K, **Greenwood CMT**, Oualkacha K. CpG-set association assessment of lipid concentration changes and DNA methylation. *BMC Proc.* 2018 Sep 17;12(Suppl 9):30. doi: 10.1186/s12919-018-0127-8. eCollection 2018.
  5. Hulea L, Gravel SP, Morita M, Cargnello M, Uchenunu O, Im YK, Lehuédé C, Ma EH, Leibovitch M, McLaughlan S, Blouin MJ, Parisotto M, Papavasiliou V, Lavoie C, Larsson O, Ohh M, Ferreira T, **Greenwood C**, Bridon G, Avizonis D, Ferbeyre G, Siegel P, Jones RG, Muller W, Ursini-Siegel J, St-Pierre J, Pollak M, Topisirovic I. Translational and HIF-1 $\alpha$ -Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. *Cell Metab.* 2018 Dec 4;28(6):817-832.e8. doi: 10.1016/j.cmet.2018.09.001. Epub 2018 Sep 20.
  6. Shokoohi F, Stephens DA, Bourque G, Pastinen T, **Greenwood CMT**, Labbe A. A hidden markov model for identifying differentially methylated sites in bisulfite sequencing data. *Biometrics.* 2018 Aug 31. doi: 10.1111/biom.12965. [Epub ahead of print]
  7. Findlay S, Heath J, Luo VM, Malina A, Morin T, Coulombe Y, Djerir B, Li Z, Samiei A, Simo-Cheyou E, Karam M, Bagci H, Rahat D, Grapton D, Lavoie EG, Dove C, Khaled H, Kuasne H, Mann KK, Klein KO, **Greenwood CM**, Tabach Y, Park M, Côté JF, Masson JY, Maréchal A, Orthwein A. SHLD2/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice. *EMBO J.* 2018 Sep 14;37(18). pii: e100158. doi: 10.15252/embj.2018100158. Epub 2018 Aug 28.
  8. Jolicoeur-Martineau A, Wazana A, Szekely E, Steiner M, Fleming AS, Kennedy JL, Meaney MJ, **Greenwood CMT**. Alternating optimization for  $G \times E$  modelling with weighted genetic and environmental scores: Examples from the MAVAN study. *Psychol Methods.* 2018 Aug 13. doi: 10.1037/met0000175. [Epub ahead of print]
  9. Chen LM, Yao N, Garg E, Zhu Y, Nguyen TTT, Pokhvisneva I, Hari Dass SA, Unternaehrer E, Gaudreau H, Forest M, McEwen LM, MacIsaac JL, Kobor MS, **Greenwood CMT**, Silveira PP, Meaney MJ, O'Donnell KJ. PRS-on-Spark (PRSoS): a novel, efficient and flexible approach for generating polygenic risk scores. *BMC Bioinformatics.* 2018 Aug 8;19(1):295. doi: 10.1186/s12859-018-2289-9.
  10. Hugué G, Schramm C, Douard E, Jiang L, Labbe A, Tihy F, Mathonnet G, Nizard S, Lemyre E, Mathieu A, Poline JB, Loth E, Toro R, Schumann G, Conrod P, Pausova Z, **Greenwood C**, Paus T, Bourgeron T, Jacquemont S; IMAGEN Consortium. Measuring and Estimating the Effect Sizes of Copy Number Variants on General Intelligence in

- Community-Based Samples. *JAMA Psychiatry*. 2018 May 1;75(5):447-457. doi: 10.1001/jamapsychiatry.2018.0039.
11. Ho B, Greenlaw K, Al Tuwaijri A, Moussette S, Martínez F, Giorgio E, Brusco A, Ferrero GB, Linhares ND, Valadares ER, Svartman M, Kalscheuer VM, Rodríguez Criado G, Laprise C, **Greenwood CMT**, Naumova AK. X chromosome dosage and presence of SRY shape sex-specific differences in DNA methylation at an autosomal region in human cells. *Biol Sex Differ*. 2018 Feb 20;9(1):10. doi: 10.1186/s13293-018-0169-7.
  12. Timpson NJ, **Greenwood CMT**, Soranzo N, Lawson DJ, Richards JB. Heritable contributions versus genetic architecture. *Nat Rev Genet*. 2018 Feb 14;19(3):185. doi: 10.1038/nrg.2018.7. No abstract available.
  13. Bhatnagar SR, Yang Y, Khundrakpam B, Evans AC, Blanchette M, Bouchard L, **Greenwood CMT**. An analytic approach for interpretable predictive models in high-dimensional data in the presence of interactions with exposures. *Genet Epidemiol*. 2018 Apr;42(3):233-249. doi: 10.1002/gepi.22112. Epub 2018 Feb 8.
  14. Kessous R, Oceau D, Klein K, Tonin PN, **Greenwood CMT**, Pelmus M, Laskov I, Kogan L, Salvador S, Lau S, Yasmeen A, Gotlieb WH. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. *Gynecol Oncol*. 2018 Mar;148(3):553-558. doi: 10.1016/j.ygyno.2018.01.017. Epub 2018 Feb 1.
  15. Forest M, O'Donnell KJ, Voisin G, Gaudreau H, MacIsaac JL, McEwen LM, Silveira PP, Steiner M, Kobor MS, Meaney MJ, **Greenwood CMT**. Agreement in DNA methylation levels from the Illumina 450K array across batches, tissues, and time. *Epigenetics*. 2018;13(1):19-32. doi: 10.1080/15592294.2017.1411443. Epub 2018 Jan 30.
  16. Sun J, Oualkacha K, Forgetta V, Zheng HF, Richards JB, Evans DS, Orwoll E, **Greenwood CMT**. Exome-wide rare variant analyses of two bone mineral density phenotypes: the challenges of analyzing rare genetic variation *Sci Rep*. 2018 Jan 9;8(1):220. doi: 10.1038/s41598-017-18385-9.
  17. Timpson NJ, **Greenwood CMT**, Soranzo N, Lawson DJ, Richards JB. Genetic architecture: the shape of the genetic contribution to human traits and disease. *Nat Rev Genet*. 2018 Feb;19(2):110-124. doi: 10.1038/nrg.2017.101. Epub 2017 Dec 11. Review.

### Melissa Henry

1. Alias A, **Henry M**. Psychosocial Effects of Head and Neck Cancer. *Oral Maxillofac Surg Clin North Am*. 2018 Nov;30(4):499-512. doi: 10.1016/j.coms.2018.06.010. Review.
2. Cohen A, Ianovski LE, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Richardson K, Black M, MacDonald C, Chartier G, Rosberger Z, **Henry M**. Barriers to psychosocial oncology service utilization in patients newly diagnosed with head and neck cancer. *Psychooncology*. 2018 Dec;27(12):2786-2793. doi: 10.1002/pon.4889. Epub 2018 Oct 9.
3. **Henry M**, Chang Y, Frenkiel S, Chartier G, Payne R, MacDonald C, Loiselle C, Black MJ, Mlynarek AM, Ehrler A, Rosberger Z, Tamilia M, Hier MP. Feelings of Disenfranchisement and Support Needs Among Patients With Thyroid Cancer. *Oncol Nurs Forum*. 2018 Sep 1;45(5):639-652. doi: 10.1188/18.ONF.639-652.
4. **Henry M**, Rosberger Z, Bertrand L, Klassen C, Hier M, Zeitouni A, Kost K, Mlynarek A, Richardson K, Black M, MacDonald C, Zhang X, Chartier G, Frenkiel S. Prevalence and Risk Factors of Suicidal Ideation among Patients with Head and Neck Cancer:

- Longitudinal Study. *Otolaryngol Head Neck Surg.* 2018 Nov;159(5):843-852. doi: 10.1177/0194599818776873. Epub 2018 Jun 5.
5. **Henry M**, Rosberger Z, Ianovski LE, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Zhang X, Fuhrmann F, Chartier G, Frenkiel S. A screening algorithm for early detection of major depressive disorder in head and neck cancer patients post-treatment: Longitudinal study. *Psychooncology.* 2018 Jun;27(6):1622-1628. doi: 10.1002/pon.4705. Epub 2018 Apr 19.
  6. **Henry M**, Frenkiel S, Chartier G, MacDonald C, Payne RJ, Black MJ, Mlynarek AM, Zeitouni A, Kost K, Loiselle C, Ehrler A, Rosberger Z, Tamilia M, Chang YX, de la Mora C, Arbaud C, Hier MP. Thyroid cancer patients receiving an interdisciplinary team-based care approach (ITCA-ThyCa) appear to display better outcomes: Program evaluation results indicating a need for further integrated care and support. *Psychooncology.* 2018 Mar;27(3):937-945. doi: 10.1002/pon.4590. Epub 2018 Jan 11.

### Michael Hier

1. Turkdogan S, Forest VI, **Hier MP**, Tamilia M, Florea A, Payne RJ. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer. *J Otolaryngol Head Neck Surg.* 2018 Sep 17;47(1):55. doi: 10.1186/s40463-018-0303-x.
2. Cohen A, Ianovski LE, Frenkiel S, **Hier M**, Zeitouni A, Kost K, Mlynarek A, Richardson K, Black M, MacDonald C, Chartier G, Rosberger Z, Henry M. Barriers to psychosocial oncology service utilization in patients newly diagnosed with head and neck cancer. *Psychooncology.* 2018 Dec;27(12):2786-2793. doi: 10.1002/pon.4889. Epub 2018 Oct 9.
3. Almarzouki H, Niazi T, **Hier M**, Mlynarek A, Lavoie I, Sultanem K. Local Failure Rate in Oropharyngeal Carcinoma Patients Treated with Intensity-modulated Radiotherapy Without High-dose Clinical Target Volume. *Cureus.* 2018 Jul 10;10(7):e2958. doi: 10.7759/cureus.2958.
4. Henry M, Chang Y, Frenkiel S, Chartier G, Payne R, MacDonald C, Loiselle C, Black MJ, Mlynarek AM, Ehrler A, Rosberger Z, Tamilia M, **Hier MP**. Feelings of Disenfranchisement and Support Needs Among Patients With Thyroid Cancer. *Oncol Nurs Forum.* 2018 Sep 1;45(5):639-652. doi: 10.1188/18.ONF.639-652.
5. Henry M, Rosberger Z, Bertrand L, Klassen C, **Hier M**, Zeitouni A, Kost K, Mlynarek A, Richardson K, Black M, MacDonald C, Zhang X, Chartier G, Frenkiel S. Prevalence and Risk Factors of Suicidal Ideation among Patients with Head and Neck Cancer: Longitudinal Study. *Otolaryngol Head Neck Surg.* 2018 Nov;159(5):843-852. doi: 10.1177/0194599818776873. Epub 2018 Jun 5.
6. Filimon S, Payne RJ, Black MJ, **Hier MP**, Mlynarek AM, Forest VI, Tamilia M. CALCITONIN SECRETORY INDEX AND UNSUSPECTED NODAL DISEASE IN MEDULLARY THYROID CARCINOMA. *Endocr Pract.* 2018 May;24(5):460-467. doi: 10.4158/EP-2017-0236.
7. Al Jassim A, Wallace T, Bouhabel S, Majdan A, **Hier M**, Forest VI, Payne R. A retrospective cohort study: do patients with graves' disease need to be euthyroid prior to surgery? *J Otolaryngol Head Neck Surg.* 2018 May 21;47(1):37. doi: 10.1186/s40463-018-0281-z.
8. Henry M, Rosberger Z, Ianovski LE, **Hier M**, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Zhang X, Fuhrmann F, Chartier G, Frenkiel S. A screening algorithm for early detection of major depressive disorder in head and neck cancer

patients post-treatment: Longitudinal study. *Psychooncology*. 2018 Jun;27(6):1622-1628. doi: 10.1002/pon.4705. Epub 2018 Apr 19.

- Henry M, Frenkiel S, Chartier G, MacDonald C, Payne RJ, Black MJ, Mlynarek AM, Zeitouni A, Kost K, Loisel C, Ehrler A, Rosberger Z, Tamilia M, Chang YX, de la Mora C, Arbaud C, **Hier MP**. Thyroid cancer patients receiving an interdisciplinary team-based care approach (ITCA-ThyCa) appear to display better outcomes: Program evaluation results indicating a need for further integrated care and support. *Psychooncology*. 2018 Mar;27(3):937-945. doi: 10.1002/pon.4590. Epub 2018 Jan 11.

### Vera Hirsh

- Melosky B, Cheema P, Agulnik J, Albadine R, Bebb DG, Blais N, Burkes R, Butts C, Card PB, Chan AMY, **Hirsh V**, Ionescu DN, Juergens R, Morzycki W, Poonja Z, Sangha R, Tehfe M, Tsao MS, Vincent M, Xu Z, Liu G. Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. *Curr Oncol*. 2018 Oct;25(5):317-328. doi: 10.3747/co.25.4379. Epub 2018 Oct 31. Review.
- Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, **Hirsh V**, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. *Oncologist*. 2018 Aug 23. pii: theoncologist.2018-0089. doi: 10.1634/theoncologist.2018-0089. [Epub ahead of print]
- Abdallah SM, **Hirsh V**. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer. *Curr Oncol*. 2018 Jun;25(Suppl 1):S9-S17. doi: 10.3747/co.25.3732. Epub 2018 Jun 13. Review.
- Melosky B, **Hirsh V**. The changing landscape of thoracic malignancies. *Curr Oncol*. 2018 Jun;25(Suppl 1):S5-S6. doi: 10.3747/co.25.4099. Epub 2018 Jun 13. No abstract available.
- Hirsh V**, Wan Y, Lin FJ, Margunato-Debay S, Ong TJ, Botteman M, Langer C. Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin. *Clin Lung Cancer*. 2018 Sep;19(5):401-409.e4. doi: 10.1016/j.clcc.2018.04.023. Epub 2018 May 7.
- Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, **Hirsh V**, Yamamoto N, O'Byrne K, Boyer M, Mok T, Peil B, Märten A, Chih-Hsin Yang J, Paz-Ares L, Park K. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. *Clin Lung Cancer*. 2018 Jul;19(4):e465-e479. doi: 10.1016/j.clcc.2018.03.009. Epub 2018 Mar 17.
- Melosky B, Chu Q, Juergens RA, Leighl N, Ionescu D, Tsao MS, McLeod D, **Hirsh V**. Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. *Cancer Treat Rev*. 2018 Apr;65:65-77. doi: 10.1016/j.ctrv.2018.02.005. Epub 2018 Feb 22. Review.
- Hirsh V**. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. *Ther Adv Med*

Oncol. 2018 Jan 22;10:1758834017753338. doi: 10.1177/1758834017753338. eCollection 2018. Review. Erratum in: Ther Adv Med Oncol. 2018 Apr 11;10:1758835918769391.

9. Wu YL, **Hirsh V**, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). *Patent*. 2018 Feb;11(1):131-141. doi: 10.1007/s40271-017-0287-z.
10. Felip E, **Hirsh V**, Popat S, Cobo M, Fülöp A, Dayen C, Trigo JM, Gregg R, Waller CF, Soria JC, Goss GD, Gordon J, Wang B, Palmer M, Ehrnrooth E, Gadgeel SM. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. *Clin Lung Cancer*. 2018 Jan;19(1):74-83.e11. doi: 10.1016/j.clcc.2017.06.002. Epub 2017 Jun 23.

#### **Maritza Hobson**

1. Hickling S, Xiang L, Jones KC, Parodi K, Assmann W, Avery S, **Hobson M**, El Naqa I. Ionizing radiation-induced acoustics for radiotherapy and diagnostic radiology applications. *Med Phys*. 2018 Jul;45(7):e707-e721. doi: 10.1002/mp.12929. Epub 2018 May 18. Review.

#### **Arezu Jahani-Asl**

1. Cheng C, Deng PY, Ikeuchi Y, Yuede C, Li D, Rensing N, Huang J, Baldrige D, Maloney SE, Dougherty JD, Constantino J, **Jahani-Asl A**, Wong M, Wozniak DF, Wang T, Klyachko VA, Bonni A. Characterization of a Mouse Model of Börjeson-Forssman-Lehmann Syndrome. *Cell Rep*. 2018 Nov 6;25(6):1404-1414.e6. doi: 10.1016/j.celrep.2018.10.043.
2. Laaper M, **Jahani-Asl A**. Regulation of neural stem cell fate decisions by mitochondrial dynamics. *Neural Regen Res*. 2018 Sep;13(9):1548-1549. doi: 10.4103/1673-5374.237115. No abstract available.

#### **Kris Jardon**

1. Piedimonte S, Richer L, Souhami L, Arseneau J, Fu L, Gilbert L, Alfieri J, **Jardon K**, Zeng XZ. Clinical significance of isolated tumor cells and micrometastasis in low-grade, stage I endometrial cancer. *J Surg Oncol*. 2018 Dec;118(7):1194-1198. doi: 10.1002/jso.25259. Epub 2018 Oct 24.
2. Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, Sundfelt K, Kjær SK, Hruban RH, Shih IM, Wang TL, Kurman RJ, Springer S, Ptak J, Popoli M, Schaefer J, Silliman N, Dobbyn L, Tanner EJ, Angarita A, Lycke M, Jochumsen K, Afsari B, Danilova L, Levine DA, **Jardon K**, Zeng X, Arseneau J, Fu L, Diaz LA Jr, Karchin R, Tomasetti C, Kinzler KW, Vogelstein B, Fader AN, Gilbert L, Papadopoulos N. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. *Sci Transl Med*. 2018 Mar 21;10(433). pii: eaap8793. doi: 10.1126/scitranslmed.aap8793.

### Nathalie Johnson

1. Contu F, Rangel-Pozzo A, Trokajlo P, Wark L, Klewes L, **Johnson NA**, Petrogiannis-Halioitis T, Gartner JG, Garini Y, Vanni R, Knecht H, Mai S. Distinct 3D Structural Patterns of Lamin A/C Expression in Hodgkin and Reed-Sternberg Cells. *Cancers (Basel)*. 2018 Aug 24;10(9). pii: E286. doi: 10.3390/cancers10090286.
2. Meti N, Esfahani K, **Johnson NA**. The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. *Cancers (Basel)*. 2018 Jun 15;10(6). pii: E204. doi: 10.3390/cancers10060204. Review.
3. Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, Riazalhosseini Y, Hébert J, Gavino C, Vinh DC, Petrogiannis-Halioitis T, Dmitrienko S, Mann KK, Morin RD, **Johnson NA**. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. *Leuk Lymphoma*. 2018 Sep;59(9):2159-2174. doi: 10.1080/10428194.2017.1413186. Epub 2018 Jan 3.

### Petr Kavan

1. Bennouna J, André T, Campion L, Hiret S, Miglianico L, Mineur L, Touchefeu Y, Artru P, Asmis T, Bouché O, Borde F, **Kavan P**, Lam YH, Rajpar LS, Emile JF, Jouffroy C, Gill S, Taïeb J. Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial. *Clin Colorectal Cancer*. 2018 Oct 19. pii: S1533-0028(18)30259-7. doi: 10.1016/j.clcc.2018.09.011. [Epub ahead of print]
2. Ibrahim M, Muanza T, Smirnow N, Sateren W, Fournier B, **Kavan P**, Palumbo M, Dalfen R, Dalzell MA. A Pilot Randomized Controlled Trial on the Effects of a Progressive Exercise Program on the Range of Motion and Upper Extremity Grip Strength in Young Adults With Breast Cancer. *Clin Breast Cancer*. 2018 Feb;18(1):e55-e64. doi: 10.1016/j.clbc.2017.06.007. Epub 2017 Jun 24.

### John Kildea

1. Montgomery L, Evans M, Liang L, Maglieri R, **Kildea J**. The effect of the flattening filter on photoneutron production at 10 MV in the Varian TrueBeam linear accelerator. *Med Phys*. 2018 Oct;45(10):4711-4719. doi: 10.1002/mp.13148. Epub 2018 Sep 14.
2. Ali F, Atanackovic J, Boyer C, Festarini A, **Kildea J**, Paterson LC, Rogge R, Stuart M, Richardson RB. Dosimetric and microdosimetric analyses for blood exposed to reactor-derived thermal neutrons. *J Radiol Prot*. 2018 Sep;38(3):1037-1052. doi: 10.1088/1361-6498/aaca9f. Epub 2018 Jun 6.
3. Montgomery L, Fava P, Freeman CR, Hijal T, Maietta C, Parker W, **Kildea J**. Development and implementation of a radiation therapy incident learning system compatible with local workflow and a national taxonomy. *J Appl Clin Med Phys*. 2018 Jan;19(1):259-270. doi: 10.1002/acm2.12218. Epub 2017 Nov 22.

### Neil Kopek

1. Pembroke CA, Fortin B, **Kopek N**. Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression. *Radiother Oncol*. 2018 Jun;127(3):493-500. doi: 10.1016/j.radonc.2018.04.022. Epub 2018 May 4.

### **Antonis Koromilas**

1. Krishnamoorthy J, Tenkerian C, Gupta J, Ghaddar N, Wang S, Darini C, Staschke KA, Ghosh A, Gandin V, Topisirovic I, Kristof AS, Hatzoglou M, Simos G, **Koromilas AE**. Downregulation of PERK activity and eIF2 $\alpha$  serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells. *Cell Death Dis.* 2018 Feb 15;9(3):254. doi: 10.1038/s41419-018-0326-2.
2. Panda DK, Bai X, Sabbagh Y, Zhang Y, Zaun HC, Karellis A, **Koromilas AE**, Lipman ML, Karaplis AC. Defective interplay between mTORC1 activity and endoplasmic reticulum stress-unfolded protein response in uremic vascular calcification. *Am J Physiol Renal Physiol.* 2018 Jun 1;314(6):F1046-F1061. doi: 10.1152/ajprenal.00350.2017. Epub 2018 Jan 10.

### **Pierre Laneuville**

1. Grand'Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, **Laneuville P**, Schechter R. Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches. *Neural Regen Res.* 2018 Nov;13(11):1871-1874. doi: 10.4103/1673-5374.239432. Review.
2. Grand'Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, **Laneuville P**, Schechter R. Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment. *Curr Med Res Opin.* 2018 Aug;34(8):1419-1430. doi: 10.1080/03007995.2018.1458023. Epub 2018 Apr 18.
3. **Laneuville P**. When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. *Curr Treat Options Oncol.* 2018 Mar 8;19(3):15. doi: 10.1007/s11864-018-0532-2. Review.

### **Magali Lecavalier-Barsoum**

1. Fawaz ZS, Kazandjian S, Tsui JM, Devic DS, **Lecavalier-Barsoum M**, Vuong T, Elakshar S, Garant A, Lavoie I, Niazi TM. What Is the Optimal Radiation Technique for Esophageal Cancer? A Dosimetric Comparison of Four Techniques. *Cureus.* 2018 Jul 16;10(7):e2985. doi: 10.7759/cureus.2985.
2. **Lecavalier-Barsoum M**, Chaudary N, Han K, Koritzinsky M, Hill R, Milosevic M. Targeting the CXCL12/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer. *Int J Cancer.* 2018 Sep 1;143(5):1017-1028. doi: 10.1002/ijc.31297. Epub 2018 Mar 5. Review.

### **Ives Levesque**

1. Xing S, Freeman CR, Jung S, Turcotte R, **Levesque IR**. Probabilistic classification of tumour habitats in soft tissue sarcoma. *NMR Biomed.* 2018 Nov;31(11):e4000. doi: 10.1002/nbm.4000. Epub 2018 Aug 16.
2. Ahmed Z, **Levesque IR**. An extended reference region model for DCE-MRI that accounts for plasma volume. *NMR Biomed.* 2018 Jul;31(7):e3924. doi: 10.1002/nbm.3924. Epub 2018 May 10.
3. Fortier V, **Levesque IR**. Phase processing for quantitative susceptibility mapping of regions with large susceptibility and lack of signal. *Magn Reson Med.* 2018 Jun;79(6):3103-3113. doi: 10.1002/mrm.26989. Epub 2017 Nov 11.

4. Alonso-Ortiz E, **Levesque IR**, Pike GB. Impact of magnetic susceptibility anisotropy at 3 T and 7 T on T2\*-based myelin water fraction imaging. *Neuroimage*. 2018 Nov 15;182:370-378. doi: 10.1016/j.neuroimage.2017.09.040. Epub 2017 Sep 25. Review.
5. Alonso-Ortiz E, **Levesque IR**, Pike GB. Multi-gradient-echo myelin water fraction imaging: Comparison to the multi-echo-spin-echo technique. *Magn Reson Med*. 2018 Mar;79(3):1439-1446. doi: 10.1002/mrm.26809. Epub 2017 Jun 27.

### Sender Liberman

1. Alhassan N, Trepanier M, Sabapathy C, Chaudhury P, **Liberman AS**, Charlebois P, Stein BL, Lee L. Risk factors for post-discharge venous thromboembolism in patients undergoing colorectal resection: a NSQIP analysis. *Tech Coloproctol*. 2018 Dec;22(12):955-964. doi: 10.1007/s10151-018-1909-8. Epub 2018 Dec 19.
2. Alhashemi M, Fiore JF Jr, Safa N, Al Mahroos M, Mata J, Pecorelli N, Baldini G, Dendukuri N, Stein BL, **Liberman AS**, Charlebois P, Carli F, Feldman LS. Incidence and predictors of prolonged postoperative ileus after colorectal surgery in the context of an enhanced recovery pathway. *Surg Endosc*. 2018 Oct 17. doi: 10.1007/s00464-018-6514-4. [Epub ahead of print]
3. Gillis C, Fenton TR, Sajobi TT, Minnella EM, Awasthi R, Loisel SÈ, **Liberman AS**, Stein B, Charlebois P, Carli F. Trimodal prehabilitation for colorectal surgery attenuates post-surgical losses in lean body mass: A pooled analysis of randomized controlled trials. *Clin Nutr*. 2018 Jul 9. pii: S0261-5614(18)31201-9. doi: 10.1016/j.clnu.2018.06.982. [Epub ahead of print]
4. Lee L, de Lacy B, Gomez Ruiz M, **Liberman AS**, Albert MR, Monson JRT, Lacy A, Kim SH, Atallah SB. A Multicenter Matched Comparison of Transanal and Robotic Total Mesorectal Excision for Mid and Low-rectal Adenocarcinoma. *Ann Surg*. 2018 Jun 18. doi: 10.1097/SLA.0000000000002862. [Epub ahead of print]
5. Balvardi S, Pecorelli N, Castelino T, Niculiseanu P, **Liberman AS**, Charlebois P, Stein B, Carli F, Mayo NE, Feldman LS, Fiore JF Jr. Measuring In-Hospital Recovery After Colorectal Surgery Within a Well-Established Enhanced Recovery Pathway: A Comparison Between Hospital Length of Stay and Time to Readiness for Discharge. *Dis Colon Rectum*. 2018 Jul;61(7):854-860. doi: 10.1097/DCR.0000000000001061.
6. Gómez-Izquierdo JC, Trainito A, Mirzakandov D, Stein BL, **Liberman AS**, Charlebois P, Pecorelli N, Feldman LS, Carli F, Baldini G. In Reply. *Anesthesiology*. 2018 Mar;128(3):683-685. doi: 10.1097/ALN.0000000000002051. No abstract available.
7. Pecorelli N, Fiore JF Jr, Kaneva P, Somasundram A, Charlebois P, **Liberman AS**, Stein BL, Carli F, Feldman LS. An app for patient education and self-audit within an enhanced recovery program for bowel surgery: a pilot study assessing validity and usability. *Surg Endosc*. 2018 May;32(5):2263-2273. doi: 10.1007/s00464-017-5920-3. Epub 2017 Nov 2.

### Carmen Loisel

1. **Loiselle CG**, Howell D, Nicoll I, Fitch M. Toward the development of a comprehensive cancer experience measurement framework. *Support Care Cancer*. 2018 Nov 16. doi: 10.1007/s00520-018-4529-y. [Epub ahead of print]
2. Perez S, Lambert SD, Lee V, **Loiselle CG**, Chan P, Gupta A, Lo K, Rosberger Z, Zelkowitz P. A fertility needs assessment survey of male cancer patients.



- Psychooncology. 2018 Dec;27(12):2747-2753. doi: 10.1002/pon.4874. Epub 2018 Oct 2.
3. Son T, Lambert S, Jakubowski A, DiCicco-Bloom B, **Loiselle CG**. Adaptation of Coping Together - a self-directed coping skills intervention for patients and caregivers in an outpatient hematopoietic stem cell transplantation setting: a study protocol. BMC Health Serv Res. 2018 Aug 29;18(1):669. doi: 10.1186/s12913-018-3483-1.

### **Koren Mann**

1. Makhani K, Chiavatti C, Plourde D, Negro Silva LF, Lemaire M, Lemarié CA, Lehoux S, **Mann KK**. Using the Apolipoprotein E Knock-Out Mouse Model to Define Atherosclerotic Plaque Changes Induced by Low Dose Arsenic. Toxicol Sci. 2018 Nov 1;166(1):213-218. doi: 10.1093/toxsci/kfy201.
2. Findlay S, Heath J, Luo VM, Malina A, Morin T, Coulombe Y, Djerir B, Li Z, Samiei A, Simo-Cheyrou E, Karam M, Bagci H, Rahat D, Grapton D, Lavoie EG, Dove C, Khaled H, Kuasne H, **Mann KK**, Klein KO, Greenwood CM, Tabach Y, Park M, Côté JF, Masson JY, Maréchal A, Orthwein A. SHLD2/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice. EMBO J. 2018 Sep 14;37(18). pii: e100158. doi: 10.15252/embj.2018100158. Epub 2018 Aug 28.
3. Zaja F, Salvi F, Rossi M, Sabattini E, Evangelista A, Ciccone G, Angelucci E, Gaidano G, Zanni M, Ladetto M, Chiappella A, Vitolo U, Zinzani PL, Califano C, Tucci A, Patti C, Pileri SA, Lenti V, Piccaluga PP, Cavallo F, Volpetti S, Perali G, Assouline S, **Mann KK**, Morin R, Alcaide M, Bushell K, Fanin R, Levis A. Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. Leuk Lymphoma. 2018 Dec;59(12):2904-2910. doi: 10.1080/10428194.2018.1452208. Epub 2018 Apr 4.
4. Pera B, Krumsiek J, Assouline SE, Marullo R, Patel J, Phillip JM, Román L, **Mann KK**, Cerchiotti L. Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway. EBioMedicine. 2018 Feb;28:80-89. doi: 10.1016/j.ebiom.2018.01.014. Epub 2018 Jan 31.
5. Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, Riazalhosseini Y, Hébert J, Gavino C, Vinh DC, Petrogiannis-Haliotis T, Dmitrienko S, **Mann KK**, Morin RD, Johnson NA. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leuk Lymphoma. 2018 Sep;59(9):2159-2174. doi: 10.1080/10428194.2017.1413186. Epub 2018 Jan 3.

### **Richard Margolese**

1. Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, **Margolese RG**, McCarron EC, Ganz PA. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx162.

### **Luke McCaffrey**

1. Toss MS, Miligy IM, Gorringer KL, **McCaffrey L**, AlKawaz A, Abidi A, Ellis IO, Green AR, Rakha EA. Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. Mod Pathol. 2018 Nov 14. doi: 10.1038/s41379-018-0180-x. [Epub ahead of print]

2. Guak H, Al Habyan S, Ma EH, Aldossary H, Al-Masri M, Won SY, Ying T, Fixman ED, Jones RG, **McCaffrey LM**, Krawczyk CM. Glycolytic metabolism is essential for CCR7 oligomerization and dendritic cell migration. *Nat Commun*. 2018 Jun 25;9(1):2463. doi: 10.1038/s41467-018-04804-6.
3. Al Habyan S, Kalos C, Szymborski J, **McCaffrey L**. Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer. *Oncogene*. 2018 Sep;37(37):5127-5135. doi: 10.1038/s41388-018-0317-x. Epub 2018 May 23.

#### **Ari Meguerditchian**

1. Syrowatka A, Hanley JA, Weir DL, Dixon WG, **Meguerditchian AN**, Tamblyn R. Ability to Predict New-Onset Psychological Distress Using Routinely Collected Health Data: A Population-Based Cohort Study of Women Diagnosed With Breast Cancer. *J Natl Compr Canc Netw*. 2018 Sep;16(9):1065-1073. doi: 10.6004/jnccn.2018.7038.
2. Henault D, Westley T, Dumitra S, Chang SL, Kremer R, Tamblyn R, Mayo N, **Meguerditchian AN**. Divergence from osteoporosis screening guidelines in older breast cancer patients treated with anti-estrogen therapy: A population-based cohort study. *Bone*. 2018 Nov;116:94-102. doi: 10.1016/j.bone.2018.06.005. Epub 2018 Jul 5.
3. Westley T, Syrowatka A, Henault D, Rho YS, Khazoom F, Chang SL, Tamblyn R, Mayo N, **Meguerditchian AN**. Patterns and predictors of emergency department visits among older patients after breast cancer surgery: A population-based cohort study. *J Geriatr Oncol*. 2018 May;9(3):204-213. doi: 10.1016/j.jgo.2017.10.003. Epub 2017 Nov 28.
4. Tamblyn R, Winslade N, Lee TC, Motulsky A, **Meguerditchian A**, Bustillo M, Elsayed S, Buckeridge DL, Couture I, Qian CJ, Moraga T, Huang A. Improving patient safety and efficiency of medication reconciliation through the development and adoption of a computer-assisted tool with automated electronic integration of population-based community drug data: the RightRx project. *J Am Med Inform Assoc*. 2018 May 1;25(5):482-495. doi: 10.1093/jamia/ocx107.

#### **Sarkis Meterissian**

1. Sabiston CM, Wrosch C, Fong AJ, Brunet J, Gaudreau P, O'Loughlin J, **Meterissian S**. Life after breast cancer: moving on, sitting down or standing still? A prospective study of Canadian breast cancer survivors. *BMJ Open*. 2018 Jul 28;8(7):e021770. doi: 10.1136/bmjopen-2018-021770.
2. Lubarsky S, Dory V, **Meterissian S**, Lambert C, Gagnon R. Examining the effects of gaming and guessing on script concordance test scores. *Perspect Med Educ*. 2018 Jun;7(3):174-181. doi: 10.1007/s40037-018-0435-8.
3. Marta GN, Poortmans P, de Barros AC, Filassi JR, Freitas-Junior R, Audisio RA, Mano MS, **Meterissian S**, DeSnyder SM, Buchholz TA, Hijal T. Reply to: Mastectomy skin flap thickness. *Eur J Surg Oncol*. 2018 Jul;44(7):1119-1120. doi: 10.1016/j.ejso.2018.04.009. Epub 2018 Apr 27. No abstract available.
4. Wong SM, Prakash I, Trabulsi N, Parsyan A, Moldoveanu D, Zhang D, Mesurrolle B, Omeroglu A, Aldis A, **Meterissian S**. Evaluating the Impact of Breast Density on Preoperative MRI in Invasive Lobular Carcinoma. *J Am Coll Surg*. 2018 May;226(5):925-932. doi: 10.1016/j.jamcollsurg.2018.01.045. Epub 2018 Feb 6.

### Catalin Mihalcioiu

1. Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, **Mihalcioiu C**, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. *JAMA Oncol*. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514. [Epub ahead of print]
2. Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, Huang X, Lvova M, Protopopov A, Vuzman D, Hogg D, Park M, Guiot MC, Petrecca K, **Mihalcioiu C**, Watson IR, Siegel PM, Rose AAN. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. *Clin Cancer Res*. 2018 Dec 15;24(24):6483-6494. doi: 10.1158/1078-0432.CCR-17-3384. Epub 2018 Jun 14.
3. Parashar S, Cheishvili D, Mahmood N, Arakelian A, Tanvir I, Khan HA, Kremer R, **Mihalcioiu C**, Szyf M, Rabbani SA. DNA methylation signatures of breast cancer in peripheral T-cells. *BMC Cancer*. 2018 May 18;18(1):574. doi: 10.1186/s12885-018-4482-7.
4. Tsui JM, **Mihalcioiu C**, Cury FL. Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab. *Cureus*. 2018 Feb 27;10(2):e2238. doi: 10.7759/cureus.2238.
5. Mahmood N, **Mihalcioiu C**, Rabbani SA. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. *Front Oncol*. 2018 Feb 12;8:24. doi: 10.3389/fonc.2018.00024. eCollection 2018. Review.

### Wilson Miller

1. Robichaud N, Hsu BE, Istomine R, Alvarez F, Blagih J, Ma EH, Morales SV, Dai DL, Li G, Souleimanova M, Guo Q, Del Rincon SV, **Miller WH Jr**, Ramón Y Cajal S, Park M, Jones RG, Piccirillo CA, Siegel PM, Sonenberg N. Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils. *Proc Natl Acad Sci U S A*. 2018 Mar 6;115(10):E2202-E2209. doi: 10.1073/pnas.1717439115. Epub 2018 Feb 20.

### Elliot Mitmaker

1. Mercier F, Laplace N, **Mitmaker EJ**, Colin C, Kraimps JL, Sebag F, Bourdy S, Duclos A, Lifante JC; CATHY Study Group. Unexpected discrepancies in hospital administrative databases can impact the accuracy of monitoring thyroid surgery outcomes in France. *PLoS One*. 2018 Dec 6;13(12):e0208416. doi: 10.1371/journal.pone.0208416. eCollection 2018.
2. Babli S, Payne RJ, **Mitmaker E**, Rivera J. Effects of Chronic Lymphocytic Thyroiditis on the Clinicopathological Features of Papillary Thyroid Cancer. *Eur Thyroid J*. 2018 Mar;7(2):95-101. doi: 10.1159/000486367. Epub 2018 Jan 10.
3. Madani A, Gornitsky J, Watanabe Y, Benay C, Altieri MS, Pucher PH, Tabah R, **Mitmaker EJ**. Measuring Decision-Making During Thyroidectomy: Validity Evidence

for a Web-Based Assessment Tool. *World J Surg.* 2018 Feb;42(2):376-383. doi: 10.1007/s00268-017-4322-y.

### Thierry Muanza

1. Ghashghaei M, Niazi TM, Heravi M, Bekerat H, Trifiro M, Paliouras M, **Muanza T**. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells. *Prostate.* 2018 Jan;78(1):64-75. doi: 10.1002/pros.23445. Epub 2017 Nov 14. Erratum in: *Prostate.* 2018 Feb;78(3):239.
2. Ibrahim M, **Muanza T**, Smirnow N, Sateren W, Fournier B, Kavan P, Palumbo M, Dalfen R, Dalzell MA. A Pilot Randomized Controlled Trial on the Effects of a Progressive Exercise Program on the Range of Motion and Upper Extremity Grip Strength in Young Adults With Breast Cancer. *Clin Breast Cancer.* 2018 Feb;18(1):e55-e64. doi: 10.1016/j.clbc.2017.06.007. Epub 2017 Jun 24.

### Alain Nepveu

1. Kaur S, Ramdzan ZM, Guiot MC, Li L, Leduy L, Ramotar D, Sabri S, Abdulkarim B, **Nepveu A**. CUX1 stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the mono-alkylating agent temozolomide. *Neuro Oncol.* 2018 Mar 27;20(4):484-493. doi: 10.1093/neuonc/nox178.

### Tamim Niazi

1. Chaddad A, **Niazi T**, Probst S, Bladou F, Anidjar M, Bahoric B. Predicting Gleason Score of Prostate Cancer Patients Using Radiomic Analysis. *Front Oncol.* 2018 Dec 18;8:630. doi: 10.3389/fonc.2018.00630. eCollection 2018.
2. Kucharczyk MJ, Gravis G, **Niazi T**. The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer. *Eur Urol Focus.* 2018 Dec 4. pii: S2405-4569(18)30372-9. doi: 10.1016/j.euf.2018.11.011. [Epub ahead of print]
3. Almarzouki H, **Niazi T**, Hier M, Mlynarek A, Lavoie I, Sultanem K. Local Failure Rate in Oropharyngeal Carcinoma Patients Treated with Intensity-modulated Radiotherapy Without High-dose Clinical Target Volume. *Cureus.* 2018 Jul 10;10(7):e2958. doi: 10.7759/cureus.2958.
4. Chaddad A, Kucharczyk MJ, **Niazi T**. Multimodal Radiomic Features for the Predicting Gleason Score of Prostate Cancer. *Cancers (Basel).* 2018 Jul 28;10(8). pii: E249. doi: 10.3390/cancers10080249.
5. **Niazi T**, Elakshar S, Stroian G. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer. *Curr Opin Support Palliat Care.* 2018 Sep;12(3):351-358. doi: 10.1097/SPC.0000000000000371.
6. Chaddad A, Sabri S, **Niazi T**, Abdulkarim B. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients. *Med Biol Eng Comput.* 2018 Dec;56(12):2287-2300. doi: 10.1007/s11517-018-1858-4. Epub 2018 Jun 19.
7. Chaddad A, Daniel P, **Niazi T**. Radiomics Evaluation of Histological Heterogeneity Using Multiscale Textures Derived From 3D Wavelet Transformation of Multispectral Images. *Front Oncol.* 2018 Apr 4;8:96. doi: 10.3389/fonc.2018.00096. eCollection 2018.
8. Ghashghaei M, **Niazi TM**, Heravi M, Bekerat H, Trifiro M, Paliouras M, Muanza T. Enhanced radiosensitization of enzalutamide via schedule dependent administration to

androgen-sensitive prostate cancer cells. *Prostate*. 2018 Jan;78(1):64-75. doi: 10.1002/pros.23445. Epub 2017 Nov 14. Erratum in: *Prostate*. 2018 Feb;78(3):239.

### Alexandre Orthwein

1. Findlay S, Heath J, Luo VM, Malina A, Morin T, Coulombe Y, Djerir B, Li Z, Samiei A, Simo-Cheyou E, Karam M, Bagci H, Rahat D, Grapton D, Lavoie EG, Dove C, Khaled H, Kuasne H, Mann KK, Klein KO, Greenwood CM, Tabach Y, Park M, Côté JF, Masson JY, Maréchal A, **Orthwein A**. SHLD2/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice. *EMBO J*. 2018 Sep 14;37(18). pii: e100158. doi: 10.15252/embj.2018100158. Epub 2018 Aug 28.
2. Collin R, Doyon K, Mullins-Dansereau V, Karam M, Chabot-Roy G, Hillhouse EE, **Orthwein A**, Lesage S. Genetic interaction between two insulin-dependent diabetes susceptibility loci, *Idd2* and *Idd13*, in determining immunoregulatory DN T cell proportion. *Immunogenetics*. 2018 Aug;70(8):495-509. doi: 10.1007/s00251-018-1060-8. Epub 2018 Apr 25.
3. Vadnais C, Chen R, Fraszczak J, Yu Z, Boulais J, Pinder J, Frank D, Khandanpour C, Hébert J, Dellaire G, Côté JF, Richard S, **Orthwein A**, Drobetsky E, Möröy T. GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. *Nat Commun*. 2018 Apr 12;9(1):1418. doi: 10.1038/s41467-018-03817-5.
4. Canny MD, Moatti N, Wan LCK, Fradet-Turcotte A, Krasner D, Mateos-Gomez PA, Zimmermann M, **Orthwein A**, Juang YC, Zhang W, Noordermeer SM, Seclen E, Wilson MD, Vorobyov A, Munro M, Ernst A, Ng TF, Cho T, Cannon PM, Sidhu SS, Sicheri F, Durocher D. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency. *Nat Biotechnol*. 2018 Jan;36(1):95-102. doi: 10.1038/nbt.4021. Epub 2017 Nov 27.

### Lawrence Panasci

1. Sharif-Askari B, Amrein L, Aloyz R, **Panasci L**. PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines. *Breast Cancer Res Treat*. 2018 Nov;172(1):23-32. doi: 10.1007/s10549-018-4888-6. Epub 2018 Jul 23.
2. Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, **Panasci L**, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. *Breast Cancer Res Treat*. 2018 Jan;167(2):485-493. doi: 10.1007/s10549-017-4538-4. Epub 2017 Oct 13.

### Valerie Panet-Raymond

1. Shakir SI, Souhami L, Petrecca K, Mansure JJ, Singh K, **Panet-Raymond V**, Shenouda G, Al-Odaini AA, Abdulkarim B, Guiot MC. Prognostic factors for progression in atypical meningioma. *J Neurosurg*. 2018 Nov 1;129(5):1240-1248. doi: 10.3171/2017.6.JNS17120.

### Morag Park

1. Findlay S, Heath J, Luo VM, Malina A, Morin T, Coulombe Y, Djerir B, Li Z, Samiei A, Simo-Cheyou E, Karam M, Bagci H, Rahat D, Grapton D, Lavoie EG, Dove C, Khaled

- H, Kuasne H, Mann KK, Klein KO, Greenwood CM, Tabach Y, **Park M**, Côté JF, Masson JY, Maréchal A, Orthwein A. SHLD2/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice. *EMBO J*. 2018 Sep 14;37(18). pii: e100158. doi: 10.15252/embj.2018100158. Epub 2018 Aug 28.
- Murali B, Ren Q, Luo X, Faget DV, Wang C, Johnson RM, Grusso T, Flanagan KC, Fu Y, Leahy K, Alspach E, Su X, Ross MH, Burnette B, Weilbaecher KN, **Park M**, Mbalaviele G, Monahan JB, Stewart SA. Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss. *Cancer Res*. 2018 Oct 1;78(19):5618-5630. doi: 10.1158/0008-5472.CAN-18-0234. Epub 2018 Aug 9.
  - Sizemore GM, Balakrishnan S, Thies KA, Hammer AM, Sizemore ST, Trimboli AJ, Cuitiño MC, Steck SA, Tozbikian G, Kladney RD, Shinde N, Das M, Park D, Majumder S, Krishnan S, Yu L, Fernandez SA, Chakravarti A, Shields PG, White JR, Yee LD, Rosol TJ, Ludwig T, **Park M**, Leone G, Ostrowski MC. Stromal PTEN determines mammary epithelial response to radiotherapy. *Nat Commun*. 2018 Jul 17;9(1):2783. doi: 10.1038/s41467-018-05266-6.
  - Hirukawa A, Smith HW, Zuo D, Dufour CR, Savage P, Bertos N, Johnson RM, Bui T, Bourque G, Basik M, Giguère V, **Park M**, Muller WJ. Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. *Nat Commun*. 2018 Jun 29;9(1):2547. doi: 10.1038/s41467-018-04864-8.
  - Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, Huang X, Lvova M, Protopopov A, Vuzman D, Hogg D, **Park M**, Guiot MC, Petrecca K, Mihalciou C, Watson IR, Siegel PM, Rose AAN. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. *Clin Cancer Res*. 2018 Dec 15;24(24):6483-6494. doi: 10.1158/1078-0432.CCR-17-3384. Epub 2018 Jun 14.
  - Bernier C, Soliman A, Gravel M, Dankner M, Savage P, Petrecca K, **Park M**, Siegel PM, Shore GC, Roulston A. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. *Anticancer Drugs*. 2018 Sep;29(8):774-785. doi: 10.1097/CAD.0000000000000653.
  - Goyette MA, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault MP, Johnson RM, Carmeliet P, Basik M, Gaboury L, Muller WJ, **Park M**, Roux PP, Gratton JP, Côté JF. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. *Cell Rep*. 2018 May 1;23(5):1476-1490. doi: 10.1016/j.celrep.2018.04.019.
  - Knight JF, Sung VYC, Kuzmin E, Couzens AL, de Verteuil DA, Ratcliffe CDH, Coelho PP, Johnson RM, Samavarchi-Tehrani P, Grusso T, Smith HW, Lee W, Saleh SM, Zuo D, Zhao H, Guiot MC, Davis RR, Gregg JP, Moraes C, Gingras AC, **Park M**. KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer. *Cell Rep*. 2018 Mar 20;22(12):3191-3205. doi: 10.1016/j.celrep.2018.02.095.
  - Robichaud N, Hsu BE, Istomine R, Alvarez F, Blagih J, Ma EH, Morales SV, Dai DL, Li G, Souleimanova M, Guo Q, Del Rincon SV, Miller WH Jr, Ramón Y Cajal S, **Park M**, Jones RG, Piccirillo CA, Siegel PM, Sonenberg N. Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils.

- Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2202-E2209. doi: 10.1073/pnas.1717439115. Epub 2018 Feb 20.
10. Manem V, Adam GA, Gruosso T, Gigoux M, Bertos N, **Park M**, Haibe-Kains B. CrosstalkNet: A Visualization Tool for Differential Co-expression Networks and Communities. *Cancer Res.* 2018 Apr 15;78(8):2140-2143. doi: 10.1158/0008-5472.CAN-17-1383. Epub 2018 Feb 19.

#### **William Parker**

1. Videtic GM, Paulus R, Singh AK, Chang JY, **Parker W**, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, Gopaul DD, Gomez Suescun JB, McGarry RC, Choy H, Bradley JD. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys.* 2018 Dec 1. pii: S0360-3016(18)34048-3. doi: 10.1016/j.ijrobp.2018.11.051. [Epub ahead of print]
2. Montgomery L, Fava P, Freeman CR, Hijal T, Maietta C, **Parker W**, Kildea J. Development and implementation of a radiation therapy incident learning system compatible with local workflow and a national taxonomy. *J Appl Clin Med Phys.* 2018 Jan;19(1):259-270. doi: 10.1002/acm2.12218. Epub 2017 Nov 22.

#### **François Patenaude**

1. Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, **Patenaude F**, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. *Can Urol Assoc J.* 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.

#### **Piotr Pater**

1. Famulari G, **Pater P**, Enger SA. Microdosimetric Evaluation of Current and Alternative Brachytherapy Sources-A Geant4-DNA Simulation Study. *Int J Radiat Oncol Biol Phys.* 2018 Jan 1;100(1):270-277. doi: 10.1016/j.ijrobp.2017.09.040. Epub 2017 Sep 25.

#### **Horacio Patrocinio**

1. Vandervoort E, **Patrocinio H**, Chow T, Soisson E, Nadeau DB. COMP Report: CPQR technical quality control guidelines for CyberKnife® Technology. *J Appl Clin Med Phys.* 2018 Mar;19(2):29-34. doi: 10.1002/acm2.12263. Epub 2018 Jan 26.

#### **Jerry Pelletier**

1. Zhang W, Liu S, Maiga RI, **Pelletier J**, Brown LE, Wang TT, Porco JA. Chemical Synthesis Enables Structural Reengineering of Aglaroxin C Leading to Inhibition Bias for HCV Infection. *J Am Chem Soc.* 2018 Dec 27. doi: 10.1021/jacs.8b11477. [Epub ahead of print]

2. Robert F, **Pelletier J**. Exploring the Impact of Single-Nucleotide Polymorphisms on Translation. *Front Genet.* 2018 Oct 30;9:507. doi: 10.3389/fgene.2018.00507. eCollection 2018. Review.
3. Cencic R, **Pelletier J**. A cautionary note on the use of cap analogue affinity resins. *Anal Biochem.* 2018 Nov 1;560:24-29. doi: 10.1016/j.ab.2018.09.001. Epub 2018 Sep 4.
4. Picard-Jean F, Brand C, Tremblay-Létourneau M, Allaire A, Beaudoin MC, Boudreault S, Duval C, Rainville-Sirois J, Robert F, **Pelletier J**, Geiss BJ, Bisailon M. Correction: 2'-O-methylation of the mRNA cap protects RNAs from decapping and degradation by DXO. *PLoS One.* 2018 Aug 9;13(8):e0202308. doi: 10.1371/journal.pone.0202308. eCollection 2018.
5. Cramer Z, Sadek J, Vazquez GG, Di Marco S, Pause A, **Pelletier J**, Gallouzi IE. eIF4A inhibition prevents the onset of cytokine-induced muscle wasting by blocking the STAT3 and iNOS pathways. *Sci Rep.* 2018 May 30;8(1):8414. doi: 10.1038/s41598-018-26625-9.
6. Picard-Jean F, Brand C, Tremblay-Létourneau M, Allaire A, Beaudoin MC, Boudreault S, Duval C, Rainville-Sirois J, Robert F, **Pelletier J**, Geiss BJ, Bisailon M. 2'-O-methylation of the mRNA cap protects RNAs from decapping and degradation by DXO. *PLoS One.* 2018 Mar 30;13(3):e0193804. doi: 10.1371/journal.pone.0193804. eCollection 2018. Erratum in: *PLoS One.* 2018 Aug 9;13(8):e0202308.
7. Katigbak A, Robert F, Paquet M, **Pelletier J**. Inducible Genome Editing with Conditional CRISPR/Cas9 Mice. *G3 (Bethesda).* 2018 May 4;8(5):1627-1635. doi: 10.1534/g3.117.300327.
8. Ramon Y Cajal S, Castellvi J, Hümmer S, Peg V, **Pelletier J**, Sonenberg N. Beyond molecular tumor heterogeneity: protein synthesis takes control. *Oncogene.* 2018 May;37(19):2490-2501. doi: 10.1038/s41388-018-0152-0. Epub 2018 Feb 21. Review.
9. Langlais D, Cencic R, Moradin N, Kennedy JM, Ayi K, Brown LE, Crandall I, Tarry MJ, Schmeing M, Kain KC, Porco JA Jr, **Pelletier J**, Gros P. Rocaglates as dual-targeting agents for experimental cerebral malaria. *Proc Natl Acad Sci U S A.* 2018 Mar 6;115(10):E2366-E2375. doi: 10.1073/pnas.1713000115. Epub 2018 Feb 20.
10. Chu J, **Pelletier J**. Therapeutic Opportunities in Eukaryotic Translation. *Cold Spring Harb Perspect Biol.* 2018 Jun 1;10(6). pii: a032995. doi: 10.1101/cshperspect.a032995. Review.
11. Chu J, Cajal SRY, Sonenberg N, **Pelletier J**. Eukaryotic initiation factor 4F-sidestepping resistance mechanisms arising from expression heterogeneity. *Curr Opin Genet Dev.* 2018 Feb;48:89-96. doi: 10.1016/j.gde.2017.11.002. Epub 2017 Nov 21. Review.
12. Choi HY, Ruel I, Malina A, Garrod DR, Oda MN, **Pelletier J**, Schwertani A, Genest J. Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis. *Eur Heart J.* 2018 Apr 7;39(14):1194-1202. doi: 10.1093/eurheartj/ehx340.

### Carmela Pepe

1. Kasymjanova G, Tran AT, Cohen V, **Pepe C**, Sakr L, Small D, Agulnik JS, Jagoe RT. The use of a standardized Chinese herbal formula in patients with advanced lung cancer: a feasibility study. *J Integr Med.* 2018 Nov;16(6):390-395. doi: 10.1016/j.joim.2018.09.001. Epub 2018 Sep 21.



### Michael Pollak

1. Justice JN, Ferrucci L, Newman AB, Aroda VR, Bahnson JL, Divers J, Espeland MA, Marcovina S, **Pollak MN**, Kritchevsky SB, Barzilai N, Kuchel GA. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. *Geroscience*. 2018 Dec;40(5-6):419-436. doi: 10.1007/s11357-018-0042-y. Epub 2018 Aug 27. Review.
2. Leuthold P, Schwab M, Hofmann U, Winter S, Rausch S, **Pollak MN**, Hennenlotter J, Bedke J, Schaeffeler E, Haag M. Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling. *J Proteome Res*. 2018 Sep 7;17(9):3039-3049. doi: 10.1021/acs.jproteome.8b00199. Epub 2018 Aug 23.
3. Wang Y, Nasiri AR, Damsky WE, Perry CJ, Zhang XM, Rabin-Court A, **Pollak MN**, Shulman GI, Perry RJ. Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. *Cell Rep*. 2018 Jul 3;24(1):47-55. doi: 10.1016/j.celrep.2018.06.008.
4. Abrahami D, Yin H, Yu OHY, **Pollak MN**, Azoulay L. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes. *Epidemiology*. 2018 Mar;29(2):246-253. doi: 10.1097/EDE.0000000000000793.
5. Sanders JL, Guo W, O'Meara ES, Kaplan RC, **Pollak MN**, Bartz TM, Newman AB, Fried LP, Cappola AR. Trajectories of IGF-I Predict Mortality in Older Adults: The Cardiovascular Health Study. *J Gerontol A Biol Sci Med Sci*. 2018 Jun 14;73(7):953-959. doi: 10.1093/gerona/glx143.

### Stéphane Richard

1. Chan LH, Zhou L, Ng KY, Wong TL, Lee TK, Sharma R, Loong JH, Ching YP, Yuan YF, Xie D, Lo CM, Man K, Artegiani B, Clevers H, Yan HH, Leung SY, **Richard S**, Guan XY, Huen MSY, Ma S. PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. *Cell Rep*. 2018 Oct 16;25(3):690-701.e8. doi: 10.1016/j.celrep.2018.09.053.
2. Calabretta S, Vogel G, Yu Z, Choquet K, Darbelli L, Nicholson TB, Kleinman CL, **Richard S**. Loss of PRMT5 Promotes PDGFR $\alpha$  Degradation during Oligodendrocyte Differentiation and Myelination. *Dev Cell*. 2018 Aug 20;46(4):426-440.e5. doi: 10.1016/j.devcel.2018.06.025. Epub 2018 Jul 26.
3. Bueno MTD, Baldascini M, **Richard S**, Lowndes NF. Recruitment of lysine demethylase 2A to DNA double strand breaks and its interaction with 53BP1 ensures genome stability. *Oncotarget*. 2018 Mar 23;9(22):15915-15930. doi: 10.18632/oncotarget.24636. eCollection 2018 Mar 23.
4. Vadnais C, Chen R, Fraszczak J, Yu Z, Boulais J, Pinder J, Frank D, Khandanpour C, Hébert J, Dellaire G, Côté JF, **Richard S**, Orthwein A, Drobetsky E, Möröy T. GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. *Nat Commun*. 2018 Apr 12;9(1):1418. doi: 10.1038/s41467-018-03817-5.

### Barbara Rivera

1. Gomes CC, Gayden T, Bajic A, Harraz OF, Pratt J, Nikbakht H, Bareke E, Diniz MG, Castro WH, St-Onge P, Sinnott D, Han H, **Rivera B**, Mikael LG, De Jay N, Kleinman CL, Valera ET, Bassenden AV, Berghuis AM, Majewski J, Nelson MT, Gomez RS,

- Jabado N. TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw. *Nat Commun.* 2018 Nov 1;9(1):4572. doi: 10.1038/s41467-018-06690-4.
2. **Rivera B.** Not so benign. *Elife.* 2018 Oct 26;7. pii: e42181. doi: 10.7554/eLife.42181.
  3. Valera ET, McConechy MK, Gayden T, **Rivera B**, Jones DTW, Wittmann A, Han H, Bareke E, Nikbakht H, Mikael L, Queiroz RG, Suazo VK, Phi JH, Kim SK, Park SH, Fukaya R, Yum MS, Ko TS, de Oliveira RS, Machado HR, Brassesco MS, do Santos AC, Simão GN, Ramalho LNZ, Neder L, Scrideli CA, Tone LG, Majewski J, Jabado N. Methylome analysis and whole-exome sequencing reveal that brain tumors associated with encephalocraniocutaneous lipomatosis are midline pilocytic astrocytomas. *Acta Neuropathol.* 2018 Oct;136(4):657-660. doi: 10.1007/s00401-018-1898-8. Epub 2018 Aug 24. No abstract available.
  4. Chong AS, Fahiminiya S, Strother D, Priest J, Albrecht S, **Rivera B**, Foulkes WD. Revisiting pleuropulmonary blastoma and atypical choroid plexus papilloma in a young child: DICER1 syndrome or not? *Pediatr Blood Cancer.* 2018 Oct;65(10):e27294. doi: 10.1002/pbc.27294. Epub 2018 Jun 26. No abstract available.
  5. **Rivera B**, Polak P, Foulkes WD. Monogenic Diseases of DNA Repair. *N Engl J Med.* 2018 Feb 1;378(5):491. doi: 10.1056/NEJMc1716072. No abstract available.
  6. de Kock L, Geoffrion D, **Rivera B**, Wagener R, Sabbaghian N, Bens S, Ellezam B, Bouron-Dal Soglio D, Ordóñez J, Sacharow S, Polo Nieto JF, Guillerman RP, Vujanic GM, Priest JR, Siebert R, Foulkes WD. Multiple DICER1-related tumors in a child with a large interstitial 14q32 deletion. *Genes Chromosomes Cancer.* 2018 May;57(5):223-230. doi: 10.1002/gcc.22523. Epub 2018 Feb 10.
  7. McCluggage WG, Irving JA, Chong AS, Clarke BA, Young RH, Foulkes WD, **Rivera B**. Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis. *Am J Surg Pathol.* 2018 Jan;42(1):137-139. doi: 10.1097/PAS.0000000000000981. No abstract available.

### **Zeev Rosberger**

1. Körner A, Roberts N, Steele RJ, Brosseau DC, **Rosberger Z**. A randomized controlled trial assessing the efficacy of a self-administered psycho-educational intervention for patients with cancer. *Patient Educ Couns.* 2018 Dec 3. pii: S0738-3991(18)31010-3. doi: 10.1016/j.pec.2018.12.002. [Epub ahead of print]
2. Aubin S, **Rosberger Z**, Hafez N, Noory MR, Perez S, Lehmann S, Batist G, Kavan P. Cancer!? I Don't Have Time for That: Impact of a Psychosocial Intervention for Young Adults with Cancer. *J Adolesc Young Adult Oncol.* 2018 Nov 28. doi: 10.1089/jayao.2017.0101. [Epub ahead of print]
3. Perez S, Zimet GD, Tatar O, Stupiansky NW, Fisher WA, **Rosberger Z**. Human Papillomavirus Vaccines: Successes and Future Challenges. *Drugs.* 2018 Sep;78(14):1385-1396. doi: 10.1007/s40265-018-0975-6.
4. Shapiro GK, Tatar O, Amsel R, Prue G, Zimet GD, Knauper B, **Rosberger Z**. Using an integrated conceptual framework to investigate parents' HPV vaccine decision for their daughters and sons. *Prev Med.* 2018 Nov;116:203-210. doi: 10.1016/j.ypmed.2018.09.017. Epub 2018 Sep 26.

5. Cohen A, Ianovski LE, Frenkiel S, Hier M, Zeitouni A, Kost K, Mlynarek A, Richardson K, Black M, MacDonald C, Chartier G, **Rosberger Z**, Henry M. Barriers to psychosocial oncology service utilization in patients newly diagnosed with head and neck cancer. *Psychooncology*. 2018 Dec;27(12):2786-2793. doi: 10.1002/pon.4889. Epub 2018 Oct 9.
6. Perez S, Lambert SD, Lee V, Loiselle CG, Chan P, Gupta A, Lo K, **Rosberger Z**, Zelkowitz P. A fertility needs assessment survey of male cancer patients. *Psychooncology*. 2018 Dec;27(12):2747-2753. doi: 10.1002/pon.4874. Epub 2018 Oct 2.
7. Tatar O, Thompson E, Naz A, Perez S, Shapiro GK, Wade K, Zimet G, Gilca V, Janda M, Kahn J, Daley E, **Rosberger Z**. Factors associated with human papillomavirus (HPV) test acceptability in primary screening for cervical cancer: A mixed methods research synthesis. *Prev Med*. 2018 Nov;116:40-50. doi: 10.1016/j.ypmed.2018.08.034. Epub 2018 Aug 31. Review.
8. Henry M, Chang Y, Frenkiel S, Chartier G, Payne R, MacDonald C, Loiselle C, Black MJ, Mlynarek AM, Ehrler A, **Rosberger Z**, Tamilia M, Hier MP. Feelings of Disenfranchisement and Support Needs Among Patients With Thyroid Cancer. *Oncol Nurs Forum*. 2018 Sep 1;45(5):639-652. doi: 10.1188/18.ONF.639-652.
9. Henry M, **Rosberger Z**, Bertrand L, Klassen C, Hier M, Zeitouni A, Kost K, Mlynarek A, Richardson K, Black M, MacDonald C, Zhang X, Chartier G, Frenkiel S. Prevalence and Risk Factors of Suicidal Ideation among Patients with Head and Neck Cancer: Longitudinal Study. *Otolaryngol Head Neck Surg*. 2018 Nov;159(5):843-852. doi: 10.1177/0194599818776873. Epub 2018 Jun 5.
10. Henry M, **Rosberger Z**, Ianovski LE, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Richardson K, Zhang X, Fuhrmann F, Chartier G, Frenkiel S. A screening algorithm for early detection of major depressive disorder in head and neck cancer patients post-treatment: Longitudinal study. *Psychooncology*. 2018 Jun;27(6):1622-1628. doi: 10.1002/pon.4705. Epub 2018 Apr 19.
11. Shapiro GK, Tatar O, Dube E, Amsel R, Knauper B, Naz A, Perez S, **Rosberger Z**. The vaccine hesitancy scale: Psychometric properties and validation. *Vaccine*. 2018 Jan 29;36(5):660-667. doi: 10.1016/j.vaccine.2017.12.043. Epub 2017 Dec 27.
12. Henry M, Frenkiel S, Chartier G, MacDonald C, Payne RJ, Black MJ, Mlynarek AM, Zeitouni A, Kost K, Loiselle C, Ehrler A, **Rosberger Z**, Tamilia M, Chang YX, de la Mora C, Arbaud C, Hier MP. Thyroid cancer patients receiving an interdisciplinary team-based care approach (ITCA-ThyCa) appear to display better outcomes: Program evaluation results indicating a need for further integrated care and support. *Psychooncology*. 2018 Mar;27(3):937-945. doi: 10.1002/pon.4590. Epub 2018 Jan 11.

### **Nader Sadeghi**

1. **Sadeghi N**, Li NW, Shokri T, Akin E, Joshi AS, Knoll S. Minimally elevated preoperative parathyroid hormone level influences the management of primary hyperparathyroidism. *Laryngoscope*. 2018 Apr;128(4):1016-1021. doi: 10.1002/lary.26699. Epub 2017 Aug 29
2. Silver E, **Sadeghi N**, Knoll S, Taheri MR. Utility of Single-Phase Computed Tomography in Identifying Parathyroid Adenomas: A Feasibility Study. *Curr Probl Diagn Radiol*. 2018 Mar - Apr;47(2):90-93. doi: 10.1067/j.cpradiol.2017.05.003. Epub 2017 May 17.

### Jan Seuntjens

1. Palmans H, Andreo P, Huq MS, **Seuntjens J**, Christaki KE, Meghzifene A. Reply to "Comments on the TRS-483 Protocol on Small field Dosimetry" [Med. Phys. 45(12), 5666-5668 (2018)]. Med Phys. 2018 Dec;45(12):5669-5671. doi: 10.1002/mp.13235. No abstract available.
2. Palmans H, Andreo P, Huq MS, **Seuntjens J**, Christaki KE, Meghzifene A. Dosimetry of small static fields used in external photon beam radiotherapy: Summary of TRS-483, the IAEA-AAPM international Code of Practice for reference and relative dose determination. Med Phys. 2018 Nov;45(11):e1123-e1145. doi: 10.1002/mp.13208. Epub 2018 Oct 17. Review.
3. Breikreutz DY, Renaud MA, **Seuntjens J**, Weil MD, Zavgorodni S, Bazalova-Carter M. Inverse optimization of low-cost kilovoltage x-ray arc therapy plans. Med Phys. 2018 Nov;45(11):5161-5171. doi: 10.1002/mp.13153. Epub 2018 Oct 1.
4. Famulari G, Renaud MA, Poole CM, Evans MDC, **Seuntjens J**, Enger SA. RapidBrachyMCTPS: a Monte Carlo-based treatment planning system for brachytherapy applications. Phys Med Biol. 2018 Aug 30;63(17):175007. doi: 10.1088/1361-6560/aad97a.
5. Perez JR, Ybarra N, Chagnon F, Lesur O, **Seuntjens J**, Naqa IE. Fluorescence Endomicroscopy Imaging of Mesenchymal Stem Cells in the Rat Lung. Curr Protoc Stem Cell Biol. 2018 May;45(1):e52. doi: 10.1002/cpsc.52. Epub 2018 May 4.
6. Watson PGF, Bekerat H, Papaconstadopoulos P, Davis S, **Seuntjens J**. An investigation into the INTRABEAM miniature x-ray source dosimetry using ionization chamber and radiochromic film measurements. Med Phys. 2018 Jun 23. doi: 10.1002/mp.13059. [Epub ahead of print]
7. Diamant A, Chatterjee A, Faria S, Naqa IE, Bahig H, Filion E, Robinson C, Al-Halabi H, **Seuntjens J**. Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)? Radiother Oncol. 2018 Sep;128(3):513-519. doi: 10.1016/j.radonc.2018.05.012. Epub 2018 May 22.
8. Kudinov KA, Cooper DR, Ha JK, Hill CK, Nadeau JL, **Seuntjens JP**, Bradforth SE. Scintillation Yield Estimates of Colloidal Cerium-Doped LaF<sub>3</sub> Nanoparticles and Potential for "Deep PDT". Radiat Res. 2018 Jul;190(1):28-36. doi: 10.1667/RR14944.1. Epub 2018 Apr 19.
9. Cooper DR, Capobianco JA, **Seuntjens J**. Radioluminescence studies of colloidal oleate-capped  $\beta$ -Na(Gd,Lu)F<sub>4</sub>:Ln<sup>3+</sup> nanoparticles (Ln = Ce, Eu, Tb). Nanoscale. 2018 Apr 26;10(16):7821-7832. doi: 10.1039/c8nr01262h.
10. Tomic N, Papaconstadopoulos P, Aldelaijan S, Rajala J, **Seuntjens J**, Devic S. Image quality for radiotherapy CT simulators with different scanner bore size. Phys Med. 2018 Jan;45:65-71. doi: 10.1016/j.ejmp.2017.11.017. Epub 2017 Dec 19.
11. Mirzakhanian L, Benmakhlouf H, Tessier F, **Seuntjens J**. Determination of k<sub>Qmsr</sub>, Q<sub>0fmsr</sub>, f<sub>ref</sub> factors for ion chambers used in the calibration of Leksell Gamma Knife Perfexion model using EGSnrc and PENELOPE Monte Carlo codes. Med Phys. 2018 Apr;45(4):1748-1757. doi: 10.1002/mp.12821. Epub 2018 Mar 23.
12. Fang D, Su X, Liu Y, Lee JC, **Seuntjens J**, Tran SD. Cell extracts from spleen and adipose tissues restore function to irradiation-injured salivary glands. J Tissue Eng Regen Med. 2018 Feb;12(2):e1289-e1296. doi: 10.1002/term.2567. Epub 2017 Nov 27.

13. Aldelaijan S, Tomic N, Papaconstadopoulos P, Schneider J, **Seuntjens J**, Shih S, Lewis D, Devic S. Technical Note: Response time evolution of XR-QA2 GafChromic™ film models. *Med Phys*. 2018 Jan;45(1):488-492. doi: 10.1002/mp.12689. Epub 2017 Dec 12.
14. Renaud J, Sarfehnia A, Bancheri J, **Seuntjens J**. Aerrow: A probe-format graphite calorimeter for absolute dosimetry of high-energy photon beams in the clinical environment. *Med Phys*. 2018 Jan;45(1):414-428. doi: 10.1002/mp.12669. Epub 2017 Dec 5.
15. Liang LH, Tomic N, Vuong T, Aldelaijan S, Bekerat H, DeBlois F, **Seuntjens J**, Devic S. Physics aspects of the Papillon technique-Five decades later. *Brachytherapy*. 2018 Jan - Feb;17(1):234-243. doi: 10.1016/j.brachy.2017.09.016.

### George Shenouda

1. Lüftner D, Dell'Acqua V, Selle F, Khalil A, Leonardi MC, De La Torre Tomás A, **Shenouda G**, Romero Fernandez J, Orecchia R, Moyal D, Seité S. Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy. *Onco Targets Ther*. 2018 Sep 17;11:5865-5872. doi: 10.2147/OTT.S155438. eCollection 2018.
2. Shakir SI, Souhami L, Petrecca K, Mansure JJ, Singh K, Panet-Raymond V, **Shenouda G**, Al-Odaini AA, Abdulkarim B, Guiot MC. Prognostic factors for progression in atypical meningioma. *J Neurosurg*. 2018 Nov 1;129(5):1240-1248. doi: 10.3171/2017.6.JNS17120.

### Chaim Shustik

1. Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, **Shustik C**, Kastiris E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. *N Engl J Med*. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.

### Sonia Skamene

1. Shi DD, DiGiovanni J, **Skamene S**, Noveroske Philbrick S, Wang Y, Barnes EA, Chow E, Sullivan A, Balboni TA. Patterns of symptom control and palliative care-focused original research articles in the International Journal of Radiation Oncology \*Biology\* Physics and the Radiotherapy and Oncology Journal, 2005-2014. *Ann Palliat Med*. 2018 Apr;7(2):249-255. doi: 10.21037/apm.2018.02.01.
2. Shi DD, Hertan LM, Lam TC, **Skamene S**, Chi JH, Groff M, Cho CH, Ferrone ML, Harris M, Chen YH, Balboni TA. Assessing the utility of the spinal instability neoplastic score (SINS) to predict fracture after conventional radiation therapy (RT) for spinal metastases. *Pract Radiat Oncol*. 2018 Sep - Oct;8(5):e285-e294. doi: 10.1016/j.prro.2018.02.001. Epub 2018 Feb 13.
3. **Skamene S**, Agarwal I, Makar M, Krishnan M, Spektor A, Hertan L, Mouw KW, Taylor A, Noveroske Philbrick S, Balboni T. Impact of a dedicated palliative radiation oncology service on the use of single fraction and hypofractionated radiation therapy among

patients with bone metastases. *Ann Palliat Med.* 2018 Apr;7(2):186-191. doi: 10.21037/apm.2017.11.02. Epub 2017 Nov 30.

4. Shi DD, Chen YH, Lam TC, Leonard D, Balboni TA, Schoenfeld A, **Skamene S**, Cagney DN, Chi JH, Cho CH, Harris M, Ferrone ML, Hertan LM. Assessing the utility of a prognostication model to predict 1-year mortality in patients undergoing radiation therapy for spinal metastases. *Spine J.* 2018 Jun;18(6):935-940. doi: 10.1016/j.spinee.2017.10.005. Epub 2017 Oct 12.

### **Susan Solymoss**

1. **Solymoss S**. Postthrombotic syndrome: simple prevention. *Blood.* 2018 Nov 22;132(21):2216-2217. doi: 10.1182/blood-2018-10-877076. No abstract available.
2. Ma KA, Kahn SR, Akaberi A, Dennie C, Rush C, Granton JT, Anderson D, Wells PS, Rodger MA, **Solymoss S**, Kovacs MJ, Rudski L, Shimony A, Hernandez P, Aaron SD, Pena E, Abikhzer G, Hirsch AM; ELOPE Study group. Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: Results of the ELOPE Study. *Res Pract Thromb Haemost.* 2018 Jun 17;2(4):670-677. doi: 10.1002/rth2.12123. eCollection 2018 Oct.
3. Alcindor T, Al-Fakeeh A, Goulding K, **Solymoss S**, Ste-Marie N, Turcotte R. Venous Thromboembolism in Patients with Sarcoma: A Retrospective Study. *Oncologist.* 2018 Sep 26. pii: theoncologist.2018-0081. doi: 10.1634/theoncologist.2018-0081. [Epub ahead of print]
4. Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Gal GL, Templier GL, Li N, MacKay E, Shah V, Shivakumar S, **Solymoss S**, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S. Erratum to: The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant who Need an Elective Surgery or Procedure: Design and Rationale. *Thromb Haemost.* 2018 Sep;118(9):1679-1680. doi: 10.1055/s-0038-1668582. Epub 2018 Sep 14. No abstract available.
5. Wan T, Rodger M, Zeng W, Robin P, Righini M, Kovacs MJ, Tan M, Carrier M, Kahn SR, Wells PS, Anderson DR, Chagnon I, **Solymoss S**, Crowther M, White RH, Vickers L, Bazarjani S, Le Gal G. Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. *Thromb Res.* 2018 Feb;162:104-109. doi: 10.1016/j.thromres.2017.11.020. Epub 2017 Dec 8.

### **Luis Souhami**

1. El-Achkar A, **Souhami L**, Kassouf W. Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy. *Curr Urol Rep.* 2018 Nov 3;19(12):108. doi: 10.1007/s11934-018-0859-z. Review.
2. Piedimonte S, Richer L, **Souhami L**, Arseneau J, Fu L, Gilbert L, Alfieri J, Jardon K, Zeng XZ. Clinical significance of isolated tumor cells and micrometastasis in low-grade, stage I endometrial cancer. *J Surg Oncol.* 2018 Dec;118(7):1194-1198. doi: 10.1002/jso.25259. Epub 2018 Oct 24.
3. Nabid A, Carrier N, Martin AG, Bahary JP, Lemaire C, Vass S, Bahoric B, Archambault R, Vincent F, Bettahar R, Duclos M, Garant MP, **Souhami L**. Duration of Androgen

- Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. *Eur Urol.* 2018 Oct;74(4):432-441. doi: 10.1016/j.eururo.2018.06.018. Epub 2018 Jul 3.
- Raman S, Moraes FY, Mendez LC, Taunk NK, Suh JH, **Souhami L**, Slotman B, Kongkham P, Spratt DE, Berlin A, Marta GN. The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials. *J Neurooncol.* 2018 Aug;139(1):195-203. doi: 10.1007/s11060-018-2860-2. Epub 2018 Jun 4.
  - Blumenthal DT, Won M, Mehta MP, Gilbert MR, Brown PD, Bokstein F, Brachman DG, Werner-Wasik M, Hunter GK, Valeinis E, Hopkins K, **Souhami L**, Howard SP, Lieberman FS, Shrieve DC, Wendland MM, Robinson CG, Zhang P, Corn BW. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. *Neuro Oncol.* 2018 Jun 18;20(7):966-974. doi: 10.1093/neuonc/noy017.
  - de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; **PORTEC study group**. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol.* 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: *Lancet Oncol.* 2018 Apr;19(4):e184.
  - Shakir SI, **Souhami L**, Petrecca K, Mansure JJ, Singh K, Panet-Raymond V, Shenouda G, Al-Odaini AA, Abdulkarim B, Guiot MC. Prognostic factors for progression in atypical meningioma. *J Neurosurg.* 2018 Nov 1;129(5):1240-1248. doi: 10.3171/2017.6.JNS17120.
  - Moraes FY, Mendez LC, Taunk NK, Raman S, Suh JH, **Souhami L**, Slotman B, Weltman E, Spratt DE, Berlin A, Marta GN. Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials. *J Neurooncol.* 2018 Feb;136(3):585-593. doi: 10.1007/s11060-017-2687-2. Epub 2017 Nov 21.
  - Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, **Souhami L**, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M. Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. *Int J Radiat Oncol Biol Phys.* 2018 Jan 1;100(1):38-44. doi: 10.1016/j.ijrobp.2017.08.038. Epub 2017 Sep 4.

#### Alan Spatz

- Wang H, **Spatz A**. Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC. *Oncotarget.* 2018 Oct 26;9(84):35472-35473. doi: 10.18632/oncotarget.26261. eCollection 2018 Oct 26. No abstract available.
- Stockley T, Souza CA, Cheema PK, Melosky B, Kamel-Reid S, Tsao MS, **Spatz A**, Karsan A. Evidence-based best practices for EGFR T790M testing in lung cancer in

- Canada. *Curr Oncol*. 2018 Apr;25(2):163-169. doi: 10.3747/co.25.4044. Epub 2018 Apr 30.
3. Popp R, Basik M, **Spatz A**, Batist G, Zahedi RP, Borchers CH. How iMALDI can improve clinical diagnostics. *Analyst*. 2018 May 15;143(10):2197-2203. doi: 10.1039/c8an00094h. Review.
  4. van Kempen LC, Wang H, Aguirre ML, **Spatz A**, Kasymjanova G, Vilacha JF, Groves MR, Agulnik J, Small D. Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC. *J Thorac Oncol*. 2018 Sep;13(9):e161-e163. doi: 10.1016/j.jtho.2018.04.020. Epub 2018 Apr 25. No abstract available.
  5. Wang H, Agulnik J, Kasymjanova G, Wang A, Jiménez P, Cohen V, Small D, Pepe C, Sakr L, Fiset PO, Auger M, Camilleri-Broet S, Alam El Din M, Chong G, van Kempen L, **Spatz A**. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. *Ann Oncol*. 2018 Jun 1;29(6):1417-1422. doi: 10.1093/annonc/mdy126.
  6. Garant A, Florianova L, Gologan A, **Spatz A**, Faria J, Morin N, Vasilevsky CA, Vuong T. . Do clinical criteria reflect pathologic complete response in rectal cancer following neoadjuvant therapy? *Int J Colorectal Dis*. 2018 Jun;33(6):727-733. doi: 10.1007/s00384-018-3033-7. Epub 2018 Mar 30.

### Barry Stein

1. Alhashemi M, Fiore JF Jr, Safa N, Al Mahroos M, Mata J, Pecorelli N, Baldini G, Dendukuri N, **Stein BL**, Liberman AS, Charlebois P, Carli F, Feldman LS. Incidence and predictors of prolonged postoperative ileus after colorectal surgery in the context of an enhanced recovery pathway. *Surg Endosc*. 2018 Oct 17. doi: 10.1007/s00464-018-6514-4. [Epub ahead of print]
2. Gillis C, Fenton TR, Sajobi TT, Minnella EM, Awasthi R, Loiselle SÈ, Liberman AS, **Stein B**, Charlebois P, Carli F. Trimodal prehabilitation for colorectal surgery attenuates post-surgical losses in lean body mass: A pooled analysis of randomized controlled trials. *Clin Nutr*. 2018 Jul 9. pii: S0261-5614(18)31201-9. doi: 10.1016/j.clnu.2018.06.982. [Epub ahead of print]
3. Balvardi S, Pecorelli N, Castelino T, Niculiseanu P, Liberman AS, Charlebois P, **Stein B**, Carli F, Mayo NE, Feldman LS, Fiore JF Jr. Measuring In-Hospital Recovery After Colorectal Surgery Within a Well-Established Enhanced Recovery Pathway: A Comparison Between Hospital Length of Stay and Time to Readiness for Discharge. *Dis Colon Rectum*. 2018 Jul;61(7):854-860. doi: 10.1097/DCR.0000000000001061.
4. Garfinkle R, Boutros M, Ghitulescu G, Vasilevsky CA, Charlebois P, Liberman S, **Stein B**, Feldman LS, Lee L. Clinical and Economic Impact of an Enhanced Recovery Pathway for Open and Laparoscopic Rectal Surgery. *J Laparoendosc Adv Surg Tech A*. 2018 Jul;28(7):811-818. doi: 10.1089/lap.2017.0677. Epub 2018 Feb 16.
5. Gómez-Izquierdo JC, Trainito A, Mirzakandov D, **Stein BL**, Liberman AS, Charlebois P, Pecorelli N, Feldman LS, Carli F, Baldini G. In Reply. *Anesthesiology*. 2018 Mar;128(3):683-685. doi: 10.1097/ALN.0000000000002051. No abstract available.
6. Lee L, Mata J, Droeser RA, Kaneva P, Liberman S, Charlebois P, **Stein B**, Fried GM, Feldman LS. Incisional Hernia After Midline Versus Transverse Specimen Extraction Incision: A Randomized Trial in Patients Undergoing Laparoscopic Colectomy. *Ann Surg*. 2018 Jul;268(1):41-47. doi: 10.1097/SLA.0000000000002615.



7. Pecorelli N, Fiore JF Jr, Kaneva P, Somasundram A, Charlebois P, Liberman AS, **Stein BL**, Carli F, Feldman LS. An app for patient education and self-audit within an enhanced recovery program for bowel surgery: a pilot study assessing validity and usability. *Surg Endosc.* 2018 May;32(5):2263-2273. doi: 10.1007/s00464-017-5920-3. Epub 2017 Nov 2.
8. Mata J, Fiore JF Jr, Pecorelli N, **Stein BL**, Liberman S, Charlebois P, Feldman LS. Predictors of adherence to enhanced recovery pathway elements after laparoscopic colorectal surgery. *Surg Endosc.* 2018 Apr;32(4):1812-1819. doi: 10.1007/s00464-017-5865-6. Epub 2017 Sep 15.

### **Gabriela Stroian**

1. Niazi T, Elakshar S, **Stroian G**. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer. *Curr Opin Support Palliat Care.* 2018 Sep;12(3):351-358. doi: 10.1097/SPC.0000000000000371.

### **Khalil Sultanem**

1. Almarzouki H, Niazi T, Hier M, Mlynarek A, Lavoie I, **Sultanem K**. Local Failure Rate in Oropharyngeal Carcinoma Patients Treated with Intensity-modulated Radiotherapy Without High-dose Clinical Target Volume. *Cureus.* 2018 Jul 10;10(7):e2958. doi: 10.7759/cureus.2958.

### **Ivan Topisirovic**

1. Hulea L, Gravel SP, Morita M, Cargnello M, Uchenunu O, Im YK, Lehuédé C, Ma EH, Leibovitch M, McLaughlan S, Blouin MJ, Parisotto M, Papavasiliou V, Lavoie C, Larsson O, Ohh M, Ferreira T, Greenwood C, Bridon G, Avizonis D, Ferbeyre G, Siegel P, Jones RG, Muller W, Ursini-Siegel J, St-Pierre J, Pollak M, **Topisirovic I**. Translational and HIF-1 $\alpha$ -Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. *Cell Metab.* 2018 Dec 4;28(6):817-832.e8. doi: 10.1016/j.cmet.2018.09.001. Epub 2018 Sep 20.
2. Boulay K, **Topisirovic I**, Mallette FA. Translation Links Nutrient Availability with Inflammation. *Trends Biochem Sci.* 2018 Nov;43(11):849-852. doi: 10.1016/j.tibs.2018.08.010. Epub 2018 Sep 14.
3. Im YK, Najyb O, Gravel SP, McGuirk S, Ahn R, Avizonis DZ, Chénard V, Sabourin V, Hudson J, Pawson T, **Topisirovic I**, Pollak M, St-Pierre J, Ursini-Siegel J. Interplay between ShcA Signaling and PGC-1 $\alpha$  Triggers Targetable Metabolic Vulnerabilities in Breast Cancer. *Cancer Res.* 2018 Sep 1;78(17):4826-4838. doi: 10.1158/0008-5472.CAN-17-3696. Epub 2018 Jun 21.
4. Roux PP, **Topisirovic I**. Signaling Pathways Involved in the Regulation of mRNA Translation. *Mol Cell Biol.* 2018 May 29;38(12). pii: e00070-18. doi: 10.1128/MCB.00070-18. Print 2018 Jun 15. Review.
5. Krishnamoorthy J, Tenkerian C, Gupta J, Ghaddar N, Wang S, Darini C, Staschke KA, Ghosh A, Gandin V, **Topisirovic I**, Kristof AS, Hatzoglou M, Simos G, Koromilas AE. Downregulation of PERK activity and eIF2 $\alpha$  serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells. *Cell Death Dis.* 2018 Feb 15;9(3):254. doi: 10.1038/s41419-018-0326-2.

6. Lindqvist LM, Tandoc K, **Topisirovic I**, Furic L. Cross-talk between protein synthesis, energy metabolism and autophagy in cancer. *Curr Opin Genet Dev.* 2018 Feb;48:104-111. doi: 10.1016/j.gde.2017.11.003. Epub 2017 Nov 25. Review.
7. Leibovitch M, **Topisirovic I**. Dysregulation of mRNA translation and energy metabolism in cancer. *Adv Biol Regul.* 2018 Jan;67:30-39. doi: 10.1016/j.jbior.2017.11.001. Epub 2017 Nov 2. Review.

#### **Anna Towers**

1. Hashemi HS, Fallone S, Boily M, **Towers A**, Kilgour RD, Rivaz H. Assessment of Mechanical Properties of Tissue in Breast Cancer-Related Lymphedema Using Ultrasound Elastography. *IEEE Trans Ultrason Ferroelectr Freq Control.* 2018 Oct 15. doi: 10.1109/TUFFC.2018.2876056. [Epub ahead of print]
2. Shallwani SM, **Towers A**. Self-Management Strategies for Malignant Lymphedema: A Case Report with 1-Year and 4-Year Follow-Up Data. *Physiother Can.* 2018 Summer;70(3):204-211. doi: 10.3138/ptc.2016-94.

#### **Michel Tremblay**

1. Pike KA, **Tremblay ML**. Protein Tyrosine Phosphatases: Regulators of CD4 T Cells in Inflammatory Bowel Disease. *Front Immunol.* 2018 Oct 31;9:2504. doi: 10.3389/fimmu.2018.02504. eCollection 2018. Review.
2. Hardy S, Kostantin E, Hatzihristidis T, Zolotarov Y, Uetani N, **Tremblay ML**. Physiological and oncogenic roles of the PRL phosphatases. *FEBS J.* 2018 Nov;285(21):3886-3908. doi: 10.1111/febs.14503. Epub 2018 May 27. Review.

#### **Josie Ursini-Siegel**

1. Hulea L, Gravel SP, Morita M, Cargnello M, Uchenunu O, Im YK, Lehuédé C, Ma EH, Leibovitch M, McLaughlan S, Blouin MJ, Parisotto M, Papavasiliou V, Lavoie C, Larsson O, Ohh M, Ferreira T, Greenwood C, Bridon G, Avizonis D, Ferbeyre G, Siegel P, Jones RG, Muller W, **Ursini-Siegel J**, St-Pierre J, Pollak M, Topisirovic I. Translational and HIF-1 $\alpha$ -Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. *Cell Metab.* 2018 Dec 4;28(6):817-832.e8. doi: 10.1016/j.cmet.2018.09.001. Epub 2018 Sep 20.
2. Im YK, Najyb O, Gravel SP, McGuirk S, Ahn R, Avizonis DZ, Chénard V, Sabourin V, Hudson J, Pawson T, Topisirovic I, Pollak M, St-Pierre J, **Ursini-Siegel J**. Interplay between ShcA Signaling and PGC-1 $\alpha$  Triggers Targetable Metabolic Vulnerabilities in Breast Cancer. *Cancer Res.* 2018 Sep 1;78(17):4826-4838. doi: 10.1158/0008-5472.CAN-17-3696. Epub 2018 Jun 21.
3. Ha JR, Ahn R, Smith HW, Sabourin V, Hébert S, Cepeda Cañedo E, Im YK, Kleinman CL, Muller WJ, **Ursini-Siegel J**. Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance. *Mol Cancer Res.* 2018 May;16(5):894-908. doi: 10.1158/1541-7786.MCR-17-0623. Epub 2018 Feb 16.

### Marie Vanhuyse

1. Olleik G, Kassouf W, Aprikian A, Hu J, **Vanhuyse M**, Cury F, Peacock S, Bonnevier E, Palenius E, Dragomir A. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. *J Natl Compr Canc Netw*. 2018 Nov;16(11):1340-1351. doi: 10.6004/jnccn.2018.7055.

### Tsafir Vanounou

1. Levy J, Zuckerman J, Garfinkle R, Acuna SA, Touchette J, **Vanounou T**, Pelletier JS. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis. *HPB (Oxford)*. 2018 Oct;20(10):905-915. doi: 10.1016/j.hpb.2018.04.001. Epub 2018 Jun 7. Review.

### Carol-Ann Vasilevsky

1. Garfinkle R, Morin N, Ghitulescu G, **Vasilevsky CA**, Boutros M. From Endoscopic Detorsion to Sigmoid Colectomy-The Art of Managing Patients with Sigmoid Volvulus: A Survey of the Members of the American Society of Colon and Rectal Surgeons. *Am Surg*. 2018 Sep 1;84(9):1518-1525.
2. Lachance S, Abou-Khalil M, **Vasilevsky CA**, Ghitulescu G, Morin N, Faria J, Boutros M. Outcomes of Ileal Pouch Excision: an American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) Analysis. *J Gastrointest Surg*. 2018 Dec;22(12):2142-2149. doi: 10.1007/s11605-018-3844-4. Epub 2018 Jul 31.
3. Garant A, Florianova L, Gologan A, Spatz A, Faria J, Morin N, **Vasilevsky CA**, Vuong T. Do clinical criteria reflect pathologic complete response in rectal cancer following neoadjuvant therapy? *Int J Colorectal Dis*. 2018 Jun;33(6):727-733. doi: 10.1007/s00384-018-3033-7. Epub 2018 Mar 30.
4. Garfinkle R, Boutros M, Ghitulescu G, **Vasilevsky CA**, Charlebois P, Liberman S, Stein B, Feldman LS, Lee L. Clinical and Economic Impact of an Enhanced Recovery Pathway for Open and Laparoscopic Rectal Surgery. *J Laparoendosc Adv Surg Tech A*. 2018 Jul;28(7):811-818. doi: 10.1089/lap.2017.0677. Epub 2018 Feb 16.
5. Abou Khalil M, Boutros M, Nedjar H, Morin N, Ghitulescu G, **Vasilevsky CA**, Gordon P, Rahme E. Incidence Rates and Predictors of Colectomy for Ulcerative Colitis in the Era of Biologics: Results from a Provincial Database. *J Gastrointest Surg*. 2018 Jan;22(1):124-132. doi: 10.1007/s11605-017-3530-y. Epub 2017 Aug 14.

### Antonio Vigano

1. Cyr C, Arboleda MF, Aggarwal SK, Balneaves LG, Daeninck P, Néron A, Prosk E, **Vigano A**. Cannabis in palliative care: current challenges and practical recommendations. *Ann Palliat Med*. 2018 Oct;7(4):463-477. doi: 10.21037/apm.2018.06.04. Epub 2018 Jun 28.

### Té Vuong

1. Fawaz ZS, Kazandjian S, Tsui JM, Devic DS, Lecavalier-Barsoum M, **Vuong T**, Elakshar S, Garant A, Lavoie I, Niazi TM. What Is the Optimal Radiation Technique for Esophageal Cancer? A Dosimetric Comparison of Four Techniques. *Cureus*. 2018 Jul 16;10(7):e2985. doi: 10.7759/cureus.2985.

- Garant A, Florianova L, Gologan A, Spatz A, Faria J, Morin N, Vasilevsky CA, **Vuong T**. Do clinical criteria reflect pathologic complete response in rectal cancer following neoadjuvant therapy? *Int J Colorectal Dis*. 2018 Jun;33(6):727-733. doi: 10.1007/s00384-018-3033-7. Epub 2018 Mar 30.
- Felfoul O, Mohammadi M, Taherkhani S, Lanauze D, Zhong Xu Y, Lafleur M, Gaboury L, Tabrizian M, **Vuong T**, Batist G, Beauchemin N, Radzioch D, Martel S. [Delivery in hypoxic tumor regions of a chemotherapeutic agent encapsulated in nanoliposomes carried by magnetoaerotactic bacteria]. *Med Sci (Paris)*. 2018 Mar;34(3):197-199. doi: 10.1051/medsci/20183403002. Epub 2018 Mar 16. French. No abstract available.
- Liang LH, Tomic N, **Vuong T**, Aldelaijan S, Bekerat H, DeBlois F, Seuntjens J, Devic S. Physics aspects of the Papillon technique-Five decades later. *Brachytherapy*. 2018 Jan - Feb;17(1):234-243. doi: 10.1016/j.brachy.2017.09.016.

### Michael Witcher

- Marques M, Jangal M, Wang LC, Kazanets A, da Silva SD, Zhao T, Lovato A, Yu H, Jie S, Del Rincon S, Mackey J, Damaraju S, Alaoui-Jamali M, **Witcher M**. Oncogenic activity of poly (ADP-ribose) glycohydrolase. *Oncogene*. 2018 Nov 20. doi: 10.1038/s41388-018-0568-6. [Epub ahead of print]
- Wang Z, Wang W, Cui YC, Pan Q, Zhu W, Gendron P, Guo F, Cen S, **Witcher M**, Liang C. HIV-1 Employs Multiple Mechanisms To Resist Cas9/Single Guide RNA Targeting the Viral Primer Binding Site. *J Virol*. 2018 Sep 26;92(20). pii: e01135-18. doi: 10.1128/JVI.01135-18. Print 2018 Oct 15.
- Simonds GR, Marvin EA, Apfel LS, Elias Z, Howes GA, **Witcher MR**, Weaver EN, Fraser JC, Synkowski JJ, Prickett JT, Rogers CM, Busch CM, Benko MJ, Sou N, Churning MJ, Summers DC, Sontheimer H. Clinical Neuroscience in Practice: An Experiential Learning Course for Undergraduates Offered by Neurosurgeons and Neuroscientists. *J Undergrad Neurosci Educ*. 2018 Jun 15;16(2):A112-A119. eCollection 2018 Spring.
- Dahabieh MS, Di Pietro E, Jangal M, Goncalves C, **Witcher M**, Braverman NE, Del Rincón SV. Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism. *Biochim Biophys Acta Rev Cancer*. 2018 Aug;1870(1):103-121. doi: 10.1016/j.bbcan.2018.07.004. Epub 2018 Aug 6. Review.
- Hampson RE, Song D, Robinson BS, Fetterhoff D, Dakos AS, Roeder BM, She X, Wicks RT, **Witcher MR**, Couture DE, Laxton AW, Munger-Clary H, Popli G, Sollman MJ, Whitlow CT, Marmarelis VZ, Berger TW, Deadwyler SA. Developing a hippocampal neural prosthetic to facilitate human memory encoding and recall. *J Neural Eng*. 2018 Jun;15(3):036014. doi: 10.1088/1741-2552/aaaed7. Epub 2018 Mar 28.
- Sandler RA, Geng K, Song D, Hampson RE, **Witcher MR**, Deadwyler SA, Berger TW, Marmarelis VZ. Designing Patient-Specific Optimal Neurostimulation Patterns for Seizure Suppression. *Neural Comput*. 2018 May;30(5):1180-1208. doi: 10.1162/NECO\_a\_01075. Epub 2018 Mar 22.
- Philipp LR, **Witcher MR**, Gross RE. A Novel Approach for Responsive Neural Stimulator Implantation With Infraclavicular Placement of the Internal Pulse Generator. *Oper Neurosurg (Hagerstown)*. 2018 Dec 1;15(6):711-719. doi: 10.1093/ons/opy025.
- Moran RJ, Kishida KT, Lohrenz T, Saez I, Laxton AW, **Witcher MR**, Tatter SB, Ellis TL, Phillips PE, Dayan P, Montague PR. The Protective Action Encoding of Serotonin

Transients in the Human Brain. *Neuropsychopharmacology*. 2018 May;43(6):1425-1435. doi: 10.1038/npp.2017.304. Epub 2018 Jan 3.

### Norma Ybarra

1. Perez JR, **Ybarra N**, Chagnon F, Lesur O, Seuntjens J, Naqa IE. Fluorescence Endomicroscopy Imaging of Mesenchymal Stem Cells in the Rat Lung. *Curr Protoc Stem Cell Biol*. 2018 May;45(1):e52. doi: 10.1002/cpsc.52. Epub 2018 May 4.

### George Zogopoulos

1. Chen YI, Miller CS, Hashim A, Valenti D, Metrakos P, Barkun J, **Zogopoulos G**, Barkun AN, Bessissow A. EUS-IR-Guided Revision of Whipple Anatomy for Concomitant Afferent and Efferent Limb Obstruction. *Am J Gastroenterol*. 2018 Dec;113(12):1747. doi: 10.1038/s41395-018-0411-2. Epub 2018 Nov 21. No abstract available.
2. Tamura K, Yu J, Hata T, Suenaga M, Shindo K, Abe T, MacGregor-Das A, Borges M, Wolfgang CL, Weiss MJ, He J, Canto MI, Petersen GM, Gallinger S, Syngal S, Brand RE, Rustgi A, Olson SH, Stoffel E, Cote ML, **Zogopoulos G**, Potash JB, Goes FS, McCombie RW, Zandi PP, Pirooznia M, Kramer M, Parla J, Eshleman JR, Roberts NJ, Hruban RH, Klein AP, Goggins M. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. *Proc Natl Acad Sci U S A*. 2018 May 1;115(18):4767-4772. doi: 10.1073/pnas.1720588115. Epub 2018 Apr 18.
3. Grant RC, Holter S, Borgida A, Dhani NC, Hedley DW, Knox JJ, Akbari MR, **Zogopoulos G**, Gallinger S. Comparison of Practice Guidelines, BRCAPro, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. *J Genet Couns*. 2018 Aug;27(4):988-995. doi: 10.1007/s10897-018-0212-1. Epub 2018 Feb 13.
4. Grant RC, Denroche RE, Borgida A, Virtanen C, Cook N, Smith AL, Connor AA, Wilson JM, Peterson G, Roberts NJ, Klein AP, Grimmond SM, Biankin A, Cleary S, Moore M, Lemire M, **Zogopoulos G**, Stein L, Gallinger S. Exome-Wide Association Study of Pancreatic Cancer Risk. *Gastroenterology*. 2018 Feb;154(3):719-722.e3. doi: 10.1053/j.gastro.2017.10.015. Epub 2017 Oct 24.